

# Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes

Laurent Poirel,<sup>a,b,c</sup> Aurélie Jayol,<sup>a,b,c</sup> Patrice Nordmann<sup>a,b,c,d</sup>

Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerland<sup>a</sup>; French INSERM European Unit, University of Fribourg (LEA-IAME), Fribourg, Switzerland<sup>b</sup>; National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland<sup>c</sup>; University of Lausanne and University Hospital Center, Lausanne, Switzerland<sup>d</sup>

<b>SUMMARY</b> .....	<b>558</b>
<b>INTRODUCTION</b> .....	<b>558</b>
Structure .....	<b>559</b>
Mechanism of Action .....	<b>559</b>
Spectrum of Activity .....	<b>560</b>
Pharmacodynamics .....	<b>560</b>
<b>USE OF COLISTIN IN HUMAN AND VETERINARY MEDICINE</b> .....	<b>560</b>
Use in Human Medicine .....	<b>560</b>
Commercial formulations .....	<b>561</b>
Routes of administration .....	<b>561</b>
Pharmacokinetics .....	<b>561</b>
Dosing regimen .....	<b>562</b>
(i) Patients with normal renal function .....	<b>562</b>
(ii) Patients with renal insufficiency .....	<b>563</b>
Toxicity .....	<b>564</b>
Use in Veterinary Medicine .....	<b>564</b>
<b>METHODS FOR SUSCEPTIBILITY TESTING</b> .....	<b>565</b>
Dilution Methods .....	<b>565</b>
Broth dilution methods .....	<b>565</b>
(i) Broth microdilution method .....	<b>565</b>
(ii) Broth macrodilution method (or tube dilution method) .....	<b>565</b>
Agar dilution method .....	<b>566</b>
Routine Susceptibility Testing Methods .....	<b>566</b>
Nonautomatic systems .....	<b>566</b>
(i) DD test (Kirby-Bauer procedure) .....	<b>566</b>
(ii) Etest strips .....	<b>567</b>
(iii) UMIC system .....	<b>567</b>
Automatic systems .....	<b>567</b>
(i) Vitek 2 system .....	<b>567</b>
(ii) Phoenix automated microbiology system .....	<b>567</b>
(iii) MicroScan system .....	<b>568</b>
(iv) Sensititre system .....	<b>568</b>
Impact of Materials on MIC Determination .....	<b>568</b>
Impact of medium .....	<b>568</b>
Impact of powder composition .....	<b>568</b>
Impact of the composition and treatment of plates .....	<b>568</b>
Presence or absence of P-80 .....	<b>569</b>
Impacts of Subcultures and Storage on MICs .....	<b>569</b>
Impact of subcultures .....	<b>569</b>
Impact of storage .....	<b>569</b>
Interpretive Criteria .....	<b>569</b>
Quality Controls .....	<b>569</b>
Correlation between MICs of Colistin and Polymyxin B .....	<b>570</b>
Qualitative Detection Techniques .....	<b>570</b>

(continued)

Published 8 March 2017

**Citation** Poirel L, Jayol A, Nordmann P. 2017. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. *Clin Microbiol Rev* 30:557–596. <https://doi.org/10.1128/CMR.00064-16>.

**Copyright** © 2017 American Society for Microbiology. All Rights Reserved.

Address correspondence to Laurent Poirel, laurent.poirel@unifr.ch.


Rapid detection of heterogeneous populations among colistin-resistant Gram-negative bacteria by use of capillary electrophoresis .....	570
Rapid detection of colistin-resistant <i>A. baumannii</i> isolates by use of the Micromax assay.....	570
Rapid detection of colistin-resistant <i>Enterobacteriaceae</i> isolates by use of the Rapid Polymyxin NP test.....	571
Selective medium.....	571
Genotypic Methods.....	571
<b>RESISTANCE MECHANISMS IN ENTEROBACTERIACEAE</b> .....	<b>572</b>
Intrinsic Resistance Mechanisms in <i>Proteus mirabilis</i> and <i>Serratia marcescens</i> .....	572
Mechanisms Responsible for Acquired Resistance in <i>Enterobacteriaceae</i> .....	572
Genes encoding LPS-modifying enzymes.....	573
(i) The <i>pmrC</i> gene.....	573
(ii) The <i>pmrHFLJKLM</i> operon and the <i>pmrE</i> gene .....	573
(iii) The <i>pmrA</i> and <i>pmrB</i> genes, which encode the PmrAB two-component system..	573
(iv) The <i>phoP</i> and <i>phoQ</i> genes, which encode the PhoPQ two-component system..	574
Regulators of the PmrAB and PhoPQ Two-Component Systems .....	574
The <i>mgrB</i> gene.....	574
The <i>crrAB</i> operon .....	574
The Intrinsic Regulator RamA.....	578
Plasmid-Mediated Resistance to Polymyxins .....	578
Other Mechanisms Contributing to Polymyxin Resistance in <i>Enterobacteriaceae</i> .....	580
Hyperproduction of CPS.....	580
Role of porins .....	583
Role of efflux pumps .....	583
Mechanisms of Polymyxin Resistance in <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> .....	583
<i>Pseudomonas aeruginosa</i> .....	583
<i>Acinetobacter baumannii</i> .....	583
<b>EPIDEMIOLOGY OF RESISTANCE TO POLYMYXINS</b> .....	<b>584</b>
General Epidemiology of Resistance to Polymyxins .....	584
North America.....	584
South America.....	584
Europe .....	584
Middle East.....	587
Africa.....	587
Asia.....	587
Risk Factors.....	587
Specific Epidemiology of the Plasmid-Mediated <i>mcr-1</i> Resistance Gene.....	588
<b>CONCLUSIONS</b> .....	<b>588</b>
<b>ACKNOWLEDGMENTS</b> .....	<b>589</b>
<b>REFERENCES</b> .....	<b>589</b>
<b>AUTHOR BIOS</b> .....	<b>596</b>

**SUMMARY** Polymyxins are well-established antibiotics that have recently regained significant interest as a consequence of the increasing incidence of infections due to multidrug-resistant Gram-negative bacteria. Colistin and polymyxin B are being seriously reconsidered as last-resort antibiotics in many areas where multidrug resistance is observed in clinical medicine. In parallel, the heavy use of polymyxins in veterinary medicine is currently being reconsidered due to increased reports of polymyxin-resistant bacteria. Susceptibility testing is challenging with polymyxins, and currently available techniques are presented here. Genotypic and phenotypic methods that provide relevant information for diagnostic laboratories are presented. This review also presents recent works in relation to recently identified mechanisms of polymyxin resistance, including chromosomally encoded resistance traits as well as the recently identified plasmid-encoded polymyxin resistance determinant MCR-1. Epidemiological features summarizing the current knowledge in that field are presented.

**KEYWORDS** Gram-negative bacteria, MCR-1, lipopolysaccharide, polymyxins, toxicity

## INTRODUCTION

Colistin (also known as polymyxin E) is a polypeptide antibiotic that was originally isolated in 1947 from the soil bacterium *Paenibacillus polymyxa* subsp. *colistinus* (1). Colistin and polymyxin B belong to the class of polymyxins, which is one of the primary classes of antibiotics with activity against most Gram-negative bacteria.



**FIG 1** Structures of colistin A and B, colistimethate A and B, and polymyxin B1 and B2.

**Structure**

The chemical structure of polymyxins is similar to that of cationic antimicrobial peptides (CAMPs) (defensins and gramicidins), which represent the first line of defense against bacterial colonization in eukaryotic cells (2). Polymyxins are cationic polypeptides that consist of a cyclic heptapeptide possessing a tripeptide side chain acylated at the N terminus by a fatty acid tail (3, 4) (Fig. 1). The inherent toxicity of colistin may be explained by the hydrophobic properties of the N-terminal fatty acyl segment, which also accounts significantly for its antimicrobial activity, and also by positions 6 and 7, which are very important (5, 6).

Colistin and polymyxin B differ by only a single amino acid in the peptide ring, with a phenylalanine in polymyxin B and a leucine in colistin (Fig. 1) (7). Polymyxin B is administered directly as an active antibiotic, whereas colistin is administered as an inactive prodrug, colistin methanesulfonate (also known as colistimethate [CMS]) (Fig. 1) (7).

The terms “colistin” and “colistimethate” are not interchangeable, since they correspond to different forms of colistin available for clinical use (4). Indeed, colistimethate sodium is a polyanionic inactive prodrug that is less toxic than colistin sulfate (Fig. 1) (4, 8). Colistimethate is formed by the reaction of colistin with formaldehyde and sodium bisulfite (9). This prodrug is transformed in aqueous media, and also *in vivo* in biological fluids, and is converted into colistin and several inactive methanesulfonated compounds (10, 11).

**Mechanism of Action**

The target of polymyxins is the outer membrane of Gram-negative bacteria. Because of an electrostatic interaction occurring between the α,γ-diaminobutyric acid (Dab) residue of the positively charged polymyxin on one side and the phosphate groups of the negatively charged lipid A membrane on the other side, divalent cations (Ca<sup>2+</sup> and Mg<sup>2+</sup>) are displaced from the negatively charged phosphate groups of membrane lipids (12). The lipopolysaccharide (LPS) is therefore destabilized, consequently increasing the permeability of the bacterial membrane, leading to leakage of the cytoplasmic

content and ultimately causing cell death (4, 13). Note that even though the LPS is the initial target, the exact mode of action of polymyxins still remains unclear.

Another antibacterial mechanism is the endotoxin effect. The endotoxin of Gram-negative pathogens corresponds to the lipid A portion of the LPS; polymyxins have the ability to bind to and neutralize this LPS molecule released during cell lysis (14).

Finally, another mode of action of the polymyxins is the inhibition of vital respiratory enzymes (inhibition of type II NADH-quinone oxidoreductases [NDH-2]) in the bacterial inner membrane (15).

### Spectrum of Activity

Polymyxins have a narrow antibacterial spectrum, mainly against common Gram-negative bacteria. They are active against most members of the *Enterobacteriaceae* family, including *Escherichia coli*, *Enterobacter* spp., *Klebsiella* spp., *Citrobacter* spp., *Salmonella* spp., and *Shigella* spp. Polymyxins also have significant activity against common nonfermentative Gram-negative bacteria, including *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Stenotrophomonas maltophilia* (13).

Conversely, some species are naturally resistant to polymyxins, including *Proteus* spp., *Morganella morganii*, *Providencia* spp., *Serratia marcescens*, *Pseudomonas mallei*, *Burkholderia cepacia*, *Chromobacterium* spp., *Edwardsiella* spp., *Brucella*, *Legionella*, *Campylobacter*, and *Vibrio cholerae*. Polymyxins are not active against Gram-negative cocci (*Neisseria* spp.), Gram-positive bacteria, and anaerobic bacteria (13).

### Pharmacodynamics

The antibacterial effect of colistin is concentration dependent (4, 16–18). The pharmacokinetic-pharmacodynamic (PK-PD) index that best predicts the antibacterial activity against *A. baumannii* and *P. aeruginosa* is the ratio of the area under the concentration-time curve for free drug from 0 to 24 h to the MIC ( $fAUC_{0-24}/MIC$ ), with this index being superior to the maximum concentration of drug in serum ( $C_{max}$ )/MIC relationship, suggesting that time-averaged exposure to colistin is more important than the achievement of high peak concentrations (19–21). An average steady-state plasma colistin concentration of 2  $\mu\text{g/ml}$  has been suggested as a reasonable target value for isolates with MICs of  $\leq 1 \mu\text{g/ml}$ , maximizing the antimicrobial activity while minimizing the risk of nephrotoxicity (22). An inadequate AUC/MIC ratio likely leads to treatment failure. The colistin antibacterial effect is extremely rapid, occurring as early as 5 min after exposure (17, 18, 23, 24).

A postantibiotic effect was observed against *Klebsiella pneumoniae*, *P. aeruginosa*, and *A. baumannii* (25). However, it is important to highlight that polymyxins have minimal postantibiotic effects at clinically relevant concentrations. Despite the major initial killing rate observed against colistin-susceptible strains exposed to colistin alone, regrowth has been reported for *A. baumannii* (17) and *K. pneumoniae* (18) in static time-kill studies. Colistin heteroresistance, a phenomenon corresponding to the emergence of a colistin-resistant subpopulation (that can grow in the presence of  $\geq 4 \mu\text{g/ml}$  of colistin) within a susceptible population (i.e., with a MIC of  $\leq 2 \mu\text{g/ml}$ ), has been observed for *A. baumannii* (26, 27), *K. pneumoniae* (18, 28), and *P. aeruginosa* (23).

## USE OF COLISTIN IN HUMAN AND VETERINARY MEDICINE

### Use in Human Medicine

After its discovery in 1947, colistin was used in Japan and Europe during the 1950s (29). Then, after its approval by the U.S. FDA in 1959, colistimethate (CMS), the inactive prodrug of colistin, replaced colistin for parenteral administration (29). Colistin and CMS have been used widely for decades for treatment of infections caused by Gram-negative bacteria. However, in the 1970s, because of their toxicity, especially nephrotoxicity (30), their use was reconsidered. They were then replaced by novel, more active and less toxic antibiotics, such as aminoglycosides, quinolones, and  $\beta$ -lactams. For 20 years, the use of colistin was restricted to ophthalmic and topical uses. Systemic or nebulized colistin was used only for cystic fibrosis patients.

However, the increasing prevalence of multidrug-resistant (MDR) Gram-negative bacteria (31), particularly *K. pneumoniae*, *A. baumannii*, and *P. aeruginosa*, has forced physicians to reintroduce systemic polymyxin as a valuable therapeutic option (4, 13, 32).

Considering the paucity of novel antibiotics, colistin is currently often the only effective antibiotic agent against MDR organisms, particularly carbapenemase-producing bacteria.


**Commercial formulations.** There are more than 30 polymyxin molecules, among which there are five main chemical compounds (polymyxins A to E), each containing multiple components. Although colistin (polymyxin E) and polymyxin B are both used in clinical practice (33), colistin is the most widely used polymyxin (23). The two most common commercially available parenteral formulations of the colistin prodrug, CMS, are Colomycin (Forest Laboratories UK Limited, Dartford, United Kingdom), primarily employed in Europe, and Coly-Mycin M Parenteral (Monarch Pharmaceuticals, Inc., Bristol, TN), primarily employed in the United States (34). Unfortunately, the vials of both formulations contain different dry powder quantities, and the two products are differently labeled, with Colomycin being labeled in international units (IU) of CMS and Coly-Mycin M Parenteral being labeled in milligrams of CMS or colistin base activity (CBA) (34). The conversion is as follows: 1 million units (MU) CMS = 80 mg CMS = 30 mg CBA (35). To add to the confusion, some other brands corresponding to generic products are now available (36). The multiplicity of terms used to express contents of vials and dose regimens unfortunately creates confusion and does not allow any meaningful comparison of data collected from studies performed in different parts of the world.

**Routes of administration.** Colistin sulfate can be administered orally as tablets and syrup for selective digestive tract decontamination (no absorption) and topically for the treatment of bacterial skin infections (13). CMS, the less toxic prodrug, has different administration routes, i.e., parenteral (including intravenous) and intramuscular, but intrathecal or intraventricular administration is also possible (13). The intramuscular injection is rarely used in clinical practice because it may be very painful locally, and also because its absorption is variable (33). Both colistin sulfate and CMS can be delivered through inhalation by aerosol therapy, but there is a higher frequency of bronchoconstriction with colistin sulfate (33). Delivery of CMS by inhalation and by the intrathecal and intraventricular routes allows much higher concentrations in lung fluid and cerebrospinal fluid, respectively, than those seen with systemic administration. Moreover, those routes of administration lead to negligible plasma exposure and are less toxic (in particularly less nephrotoxic) (22).

In aqueous solutions, colistimethate sodium is transformed into colistin; therefore, it should be administered shortly after reconstitution to avoid the toxicity associated with colistin (37).

**Pharmacokinetics.** Because of their discovery and their introduction into clinical use more than 50 years ago, polymyxins were never subjected to the drug development approval process currently required by international drug regulatory authorities. Consequently, the PK and PD data on the rational use of polymyxins (maximizing antibacterial activity and minimizing toxicity and development of resistance) were not available until recently. The fact that, until recently, plasma concentrations of CMS and formed colistin could not be differentiated because of a lack of suitable techniques was another obstacle limiting progress in this area. The recent development of chromatographic methods allowing quantitative assessment of each compound separately significantly contributed to the renewed interest in prescribing colistin and colistimethate (38, 39). It was clearly demonstrated that the observed antimicrobial activity results from the action of colistin itself, which is generated *in vivo* when CMS is given. For accurate PK information, a prerequisite is to quantify separately the inactive prodrug (CMS) and the active entity (colistin) (34).

After its parenteral administration, a large proportion of CMS is eliminated mainly through the kidneys by glomerular filtration and tubular secretion (Fig. 2A) (11).



**FIG 2** Overview of the pharmacokinetic pathways for colistimethate (CMS) and colistin (A) and for polymyxin B (B). The thicknesses of the arrows indicate the relative magnitudes of the respective clearance pathways when kidney function is normal. CMS includes fully and all partially methanesulfonated derivatives of colistin. After administration of CMS, extensive renal excretion of the prodrug occurs, with some of the excreted CMS being converted to colistin within the urinary tract. (The figure is based in part on data from reference 7.)

Because in a healthy individual the clearance of CMS by the kidneys is much higher than its conversion clearance to colistin, no more than 20 to 25% of a CMS dose is hydrolyzed *in vivo* into an active colistin entity (7). Consequently, the colistin concentrations resulting from the original CMS administration are low. In contrast to CMS, colistin is eliminated predominantly by a nonrenal way because of its extensive renal tubular reabsorption (Fig. 2A) (11, 40). Although colistin is poorly excreted in urine, the urinary concentration of colistin may be relatively high after administration of CMS due to the conversion of CMS (highly excreted by the kidneys) into colistin within the urinary tract (7).

In contrast to colistin, polymyxin B is administered directly in its active antibacterial form. As for colistin formed from CMS, polymyxin B is subject to very extensive renal tubular reabsorption and is thus eliminated mainly by a nonrenal clearance mechanism(s) (Fig. 2B) (7).

**Dosing regimen.** Due to renewed interest in its use in the context of infections caused by multidrug-resistant bacteria, and considering the increasing rates of resistance to colistin currently observed, CMS has to be administered carefully. In particular, the regimens allowing maximal antibacterial activity and minimal development of resistance have to be defined accurately, since the regimens need to minimize adverse effects (23). A study analyzing product data characteristics of intravenous CMS revealed a lack of uniformity between manufacturers, with quite broad variations in term of indications, dose regimens (3 to 12 MU/day), and PK (36). Moreover, dosing regimens given by manufacturers are often discordant with the dosing regimens recommended by the recent literature (21, 34, 41).

(i) **Patients with normal renal function.** The currently used dosage regimens of CMS generate suboptimal exposure to colistin in many critically ill patients, in particular in renally competent patients. Two studies reported low plasma colistin  $C_{max}$  values

following administration of 174 mg to 250 mg (2 to 3 MU) of CMS every 8 or 12 h, with steady-state levels of 1.15 to 5.14  $\mu\text{g/ml}$  or 0.68 to 4.65  $\mu\text{g/ml}$ , respectively (42). Moreover, a significant delay in obtaining steady-state plasma concentrations of formed colistin was reported for CMS treatment started without administration of a loading dose (43). In the latter study, concentrations of colistin in the plasma were reported to be below the MIC breakpoint (2  $\mu\text{g/ml}$ ), which is a main drawback considering that a delayed initiation of appropriate antibiotic therapy has been shown to be associated with increased mortality rates, in particular for critically ill patients (44). In addition, low colistin concentrations may induce the amplification of colistin-resistant subpopulations (18, 45). Interestingly, on consideration of the current dose range product recommendations for CMS, it was confirmed that its administration at the upper limit to patients with normal renal function resulted in low and potentially suboptimal plasma colistin concentrations, especially when the MIC for the infecting bacterial strain was in the upper range (2  $\mu\text{g/ml}$ ) or if the infection was associated with a high bacterial inoculum (21). That study also revealed that steady-state plasma colistin concentrations are highly variable, with up to a 10-fold range achieved across patients at a given creatinine clearance (21).

In contrast, there is a relatively low interpatient variability (3.3-fold) across a wide range of creatinine clearance values following administration of polymyxin B (46). Considering that polymyxin B is not given as a prodrug, it is easier to rapidly achieve a desired plasma concentration of polymyxin B (46).

There is no consensus about dosing regimens, even though recently published dosing suggestions seem to be widely accepted (19). Compared to those suggested by the manufacturers, the regimens in recent studies support the administration of a loading dose and of higher doses of CMS in order to achieve adequate colistin concentrations leading to a better therapeutic effect (21, 41, 47). The dosing regimen currently recommended by the recent literature (for patients with good renal function) is a loading dose of 4.5 MU of CMS followed by maintenance doses of 4.5 MU twice daily (48–50). A colistin-containing combination therapy has to be considered if the infecting pathogen shows an MIC of colistin above 1  $\mu\text{g/ml}$ , if there is a high inoculum, or in dealing with deep-seated infections (e.g., in lungs). One therefore has to consider adding antibiotics to colistin regimens, especially for patients with relatively normal renal function (21, 22).

Data about the pharmacokinetics, effectiveness, and safety of polymyxins were recently reviewed by the European Medicines Agency (EMA). There have been recommended changes in terms of product information in order to ensure the safer use of polymyxins (51). According to the EMA, polymyxins should be reserved for the treatment of serious infections due to aerobic Gram-negative pathogens with limited treatment options (51). Also, they should be given with another suitable antibiotic when possible. The recommended dose for CMS in adults is 9 MU daily in 2 or 3 divided doses as a slow intravenous infusion. For dealing with critically ill patients, a loading dose of 9 MU should be given. For patients with renal impairment, doses should obviously be reduced, with consideration of the creatinine clearance.

Because the efficacy and toxicity of colistin are dose dependent, it is crucial that optimal dose regimens be used to maximize the antimicrobial activity and to minimize adverse effects and the development of resistance. This is especially important for critically ill patients, as they are most at risk for high morbidity and mortality (52).

**(ii) Patients with renal insufficiency.** A study showed that colistin levels were elevated in patients with renal insufficiency, presumably due to decreased elimination of the antibiotic generating a higher rate of conversion of CMS to colistin (43). Development of nephrotoxicity is consequently higher in patients with renal insufficiency than in patients with normal renal function (53).

Dalfino et al. (54) suggested a new dose adjustment for high-dose colistin therapy for patients with renal insufficiency. For patients with creatinine clearance of 20 to 50 ml/min, they recommend a loading dose of 9 MU and maintenance doses of 4.5 MU

every 24 h. For patients with creatinine clearance of <20 ml/min, they recommend a loading dose of 9 MU and maintenance doses of 4.5 MU every 48 h (21, 55).

**Toxicity.** Rates of toxicity following intravenous administration of CMS are considered lower today than those observed in previous studies, and it has to be mentioned that the criteria for defining toxicity have also been updated (56). The lower toxicity may be related to the fact that there are fewer chemical impurities in CMS but also to the fact that monitoring in intensive care units (ICUs) is better nowadays and the coadministration of other nephrotoxic drugs is significantly avoided (33).

Colistin has a narrow therapeutic window, and major adverse effects related to its parenteral use are neurotoxicity and nephrotoxicity. Neurotoxicity is dose dependent and reversible (55) and may cause peripheral and facial paresthesia, weakness, dizziness/vertigo, visual disturbances, confusion, ataxia, and neuromuscular blockade, even leading to respiratory failure or apnea (56). The most common neurotoxicological effect is paresthesia (occurring in 27% of patients), and there is no report of neuromuscular blockade or apnea in the recent literature (56). Nephrotoxicity is the most common and concerning adverse effect, especially with the newly recommended high-dose regimen. Similarly to neurotoxicity, nephrotoxicity is dose dependent. The risk of colistin-associated nephrotoxicity increases with plasma colistin concentrations above 2.5 to 3  $\mu\text{g/ml}$ , as revealed by recent PK-PD analyses (57). Other risk factors for nephrotoxicity include coadministration of other drugs that are also nephrotoxic (anti-inflammatory drugs, vancomycin, or aminoglycoside antibiotics) and patient-related factors (advanced age, male sex, hypoalbuminemia, hyperbilirubinemia, preexisting chronic kidney disease, and severity of illness) (33, 56). Nephrotoxicity is reported to be a rapid-onset effect, with most cases occurring within the first week of treatment, and is mostly reversible (33, 55). Rates of nephrotoxicity in recent studies ranged from 6% to 55% (33). The large range of nephrotoxicity rates may be explained partially by different definitions of renal failure, the dosing regimens used, the concomitant administration of nephrotoxic drugs, and the use of colistin monitoring to adapt dosing regimens. The RIFLE (risk–injury–failure–loss–end-stage renal disease) classification is used to determine colistin-associated nephrotoxicity (58).

Two recent comparative studies involving large numbers of patients showed that the nephrotoxicity rates were lower for polymyxin B than for CMS/colistin (59, 60).

### Use in Veterinary Medicine

As opposed to the case in human medicine, in veterinary medicine colistin has been used extensively for decades for the treatment and prevention of infectious diseases. The majority of polymyxin consumption corresponds to orally administered forms, with different formulations (premix, powder, or oral solutions). The main usage is related to enterobacterial infections, and in particular to gastrointestinal infections caused by *E. coli* in poultry and pigs within intensive husbandry systems (61). Apart from this common usage for treating infections caused by *Enterobacteriaceae*, another usage corresponds to growth promotion, which is a common practice worldwide. Furthermore, the fact that only a thin line exists between oral metaphylactic therapy, preventive starter rations, and growth promotion adds to the problem. In 2011, polymyxins were the fifth most sold class of antimicrobials (7%) for treating food-producing animals in Europe (61).

Despite this extensive use in veterinary medicine, the resistance rate to colistin in *E. coli* strains recovered from healthy animals remains <1% in many European countries (62). However, resistance to colistin has increasingly been reported (10%) among porcine-pathogenic *E. coli* strains in Belgium (63), and the emergence of resistance has been described for cattle (64). Moreover, some recent data revealed the possibility of horizontal transmission from farm animals to humans in Asia (65). Given the increasing need to retain the efficacy of colistin to treat MDR infections in humans, the potential for spreading colistin-resistant isolates from animals to humans, and the recent identification of colistin-resistant *Enterobacteriaceae* organisms harboring a plasmid-borne colistin resistance determinant in animals and food products (see below), the use of colistin in veterinary medicine is being reevaluated. As a very recent example, the



formal Ministry of Agriculture of China decided to ban colistin as a feed additive for animals (66). Also, the European Medicines Agency provided a position paper in June 2016, in which updated advice on the use of colistin products in animals within the European Union is provided (67).

## METHODS FOR SUSCEPTIBILITY TESTING

Despite such a long term of clinical use (decades), the optimal method for polymyxin susceptibility testing still remains undefined. However, the recent emergence of MDR Gram-negative bacteria and the subsequent increased use of colistin prompted the scientific community to develop rapid and reliable methods to determine the susceptibility of isolates to polymyxins, as this is now an urgent need in clinical laboratories. Polymyxin susceptibility testing is now a major challenge, as human infections with colistin-resistant Gram-negative bacteria are associated with higher patient mortality (68). The difficulties in testing susceptibility to polymyxins are diverse, including poor diffusion of polymyxins into agar, the inherent cationic properties of polymyxins, the occurrence of heteroresistance to polymyxins in many species, and the lack of a reliable reference method that may allow reliable comparisons of commercial tests (69, 70).

### Dilution Methods

The aim of dilution methods is to determine the MIC, corresponding to the lowest concentration of polymyxin that inhibits visible bacterial growth after an incubation of 16 to 24 h at  $35 \pm 2^\circ\text{C}$ .

**Broth dilution methods.** Broth dilution is a technique in which a bacterial suspension at a predetermined concentration is tested against various concentrations of antimicrobial agent in a liquid medium with a predetermined formulation. Two types of broth dilution methods are available: (i) the broth macrodilution method, performed with a minimum volume of 2 ml in standard test tubes; and (ii) the broth microdilution (BMD) method, performed with a volume of 0.05 to 0.1 ml in microtitration trays.

**(i) Broth microdilution method.** BMD is the reference susceptibility test method. It is currently the only method recommended by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (71, 72) for polymyxin antimicrobial susceptibility testing.

According to CLSI recommendations, BMD is performed with cation-adjusted Mueller-Hinton broth (CA-MHB), a range of 2-fold dilutions of polymyxins (ranging from 0.12 to 512  $\mu\text{g/ml}$ ), and a final bacterial inoculum of  $5 \times 10^5$  CFU/ml in each well (73). BMD is considered to be the optimal method and is currently recommended for susceptibility testing in the recent document proposed by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group ([http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/General\\_documents/Recommendations\\_for\\_MIC\\_determination\\_of\\_colistin\\_March\\_2016.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf)).

However, BMD is quite laborious, and manual preparation (if the technique used is not an automated one) of antibiotic solutions may lead to significant errors. It is therefore not adaptable for most clinical microbiology laboratories. Furthermore, non-reproducible and noninterpretable MIC results have been reported due to the presence of skip wells (i.e., wells that exhibit no growth, whereas growth is observed in wells with higher antibiotic concentrations) for *Enterobacter* species (69), *P. aeruginosa* (72), and *A. baumannii* (73). This phenomenon might be caused by heteroresistant subpopulations for *Enterobacter* spp. (69). In parallel, "skip well" isolates of *P. aeruginosa* have been found to have increased expression of the *pmrAB*, *phoQ*, and *arn* genes related to changes in the LPS structure, reducing the potential binding sites of polymyxins (74).

Nevertheless, BMD currently remains the reference method for determination of MICs because of its reproducibility, reliability, and possibility of automation.

**(ii) Broth macrodilution method (or tube dilution method).** The growth medium (CA-MHB), the inoculum bacterial suspension, the preparation of 2-fold dilutions of polymyxins, the incubation conditions, and the reading of the plate are identical to those for the broth microdilution method. The only difference is the volume of growth

medium and the use of test tubes instead of trays. When evaluated against BMD results, the results of the broth macrodilution method showed the highest agreement (83%) compared to other available methods, and no false susceptibility was observed (70).

**Agar dilution method.** Agar dilution is another reference method that relies on various concentrations of polymyxin molecules in Mueller-Hinton agar (usually 2-fold serial dilutions), followed by the seeding of a defined bacterial inoculum onto the agar plate. In accordance with the CLSI recommendations, the polymyxin powder is dissolved in sterile water and added to molten MH agar to provide 2-fold dilutions (usually ranging from 0.12  $\mu\text{g/ml}$  to 512  $\mu\text{g/ml}$ ) (70, 71). A bacterial inoculum corresponding to a 0.5 McFarland standard (approximately  $10^8$  CFU/ml) is prepared, and then 10-fold dilutions are performed. One microliter of this dilution is spotted manually or with an automated system, and each spot consequently inoculates  $10^4$  CFU of bacteria.

Agar dilution may theoretically avoid the adsorption of colistin to the plates, but no study has measured the colistin concentration in agar dilution plates to confirm this hypothesis. Numerous studies have demonstrated a strong correlation between agar dilution and BMD (70, 75, 76), with the exception of results obtained with *P. aeruginosa* and *S. maltophilia* isolates from cystic fibrosis patients (77, 78). One advantage of the agar dilution method is the ability to test multiple strains on the same plate and the possibility to semiautomate the method. However, the agar dilution method also presents some disadvantages, as it is very laborious if not automated and the plates (not available from commercial sources) must be used within a week of preparation.

Many studies have employed the agar dilution method as a standard; however, BMD remains the primary reference method for polymyxin MIC testing. In a recent document proposed by the joint CLSI-EUCAST Polymyxin Breakpoints Working Group, it is stated that agar dilution is not recommended for susceptibility testing ([http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/General\\_documents/Recommendations\\_for\\_MIC\\_determination\\_of\\_colistin\\_March\\_2016.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/General_documents/Recommendations_for_MIC_determination_of_colistin_March_2016.pdf)).

### Routine Susceptibility Testing Methods

**Nonautomatic systems. (i) DD test (Kirby-Bauer procedure).** The disk diffusion (DD) test refers to the diffusion of a given concentration of polymyxin from disks into MH agar that has been seeded with a defined bacterial inoculum. According to the CLSI and EUCAST guidelines, the disk diffusion test is performed by applying a bacterial inoculum corresponding to a 0.5 McFarland standard (approximately  $10^8$  CFU/ml) suspended in 0.85% NaCl onto the entire surface of an MH agar plate by use of a sterile cotton swab. Paper disks impregnated with polymyxin are placed on the inoculated agar surface. Following the CLSI guidelines, the contents of colistin and polymyxin B on the paper disks are 10  $\mu\text{g}$  and 300 U, respectively (72), while following the EUCAST recommendations, the colistin content is 50  $\mu\text{g}$  (71). The growth inhibition zone diameter around the disk is measured after incubation for 16 to 24 h at  $35 \pm 2^\circ\text{C}$ . The diameter of the inhibition zone is proportional to the bacterial susceptibility to polymyxins and inversely correlates with the MIC of the bacterial strain.

The DD test is easy and cheap and does not require specific equipment. These advantages explain why this method is commonly used as a primary test method to screen large numbers of isolates. However, the poor and slow diffusion of polymyxins through agar gives small zones of inhibition and limits the predictive accuracy of the DD test. In fact, many studies showed that the DD test is a nonreliable method for measuring susceptibility to colistin for Gram-negative rods, giving an unacceptable and very high rate of false susceptibility (up to 35%) compared to that with dilution methods (76, 78–80). A higher concentration of colistin in the disk (50  $\mu\text{g}$  as recommended by EUCAST versus 10  $\mu\text{g}$  as recommended by CLSI) does not improve the reliability of the test (80). Susceptible results should therefore be confirmed by dilution tests. On the other hand, no false resistance results are found with this method (80).

This method is not reliable and should be abandoned. For human medicine, EUCAST recommends that precise MIC determination be mandatory before clinical use and no longer provides disk breakpoints (71). For veterinary medicine, EUCAST recommends

precise determination of the MIC each time that the diameter of the inhibition zone is between 15 and 18 mm for a given strain.

(ii) **Etest strips.** Etests are thin plastic test strips impregnated with increasing antibiotic concentrations. MICs are read with the concentration scale marked on the upper surface. According to the manufacturer's recommendations, this method is performed by applying a bacterial inoculum of approximately  $10^8$  CFU/ml (turbidimetry of a 0.5 McFarland standard) suspended in 0.85% NaCl onto the entire surface of an MH agar plate by use of a sterile cotton swab. Etest strips containing a colistin concentration gradient (ranging from 0.016 to 256  $\mu\text{g/ml}$ ) are placed on the inoculated agar surface, and the MIC is determined after incubation for 16 to 24 h at  $35 \pm 2^\circ\text{C}$ . The MIC value is defined by the intersection of the lower part of the ellipse-shaped growth inhibition area with the test strip. When the intersection occurs around the MIC endpoint, the highest MIC intersection is recorded (75). When small colonies grow within the zone of inhibition, the strain must be considered heteroresistant to colistin, and the highest MIC intersection is recorded (75, 81).

Several studies, notably including few resistant isolates, found an excellent correlation between the Etest and reference techniques (75, 76, 80, 82). However, studies including larger numbers of resistant isolates reported high rates of false susceptibility (up to 32%) for Gram-negative rods compared to those with dilution methods (69, 70, 78, 83). The Etest method may fail to detect resistance to colistin even when isolates exhibit high MICs by dilution methods (70, 83). In addition, there are discrepancies between MICs measured by Etest and MICs measured by dilution methods (70, 82). It has been reported that the Etest strip method underestimates the level of resistance of polymyxin-resistant strains ( $\text{MIC} \geq 4 \mu\text{g/ml}$ ) and overestimates the MIC values for susceptible strains ( $\text{MIC} < 4 \mu\text{g/ml}$ ) (70).

This method is easy to perform but is relatively expensive and does not reliably detect colistin-resistant isolates. As for the disk diffusion test, susceptibility results obtained by Etest require a 24-h delay.

(iii) **UMIC system.** The UMIC system (Biocentric) consists of broth microdilution unitary panels in which the wells contain prediluted lyophilized colistin at concentrations ranging from 0.06 to 64  $\mu\text{g/ml}$ . The inoculation is performed manually, and the required incubation time ranges from 18 to 24 h. The performance of this system has not yet been evaluated.

**Automatic systems.** Use of instruments may allow susceptibility testing to be performed in a shorter period than that required for manual methods, as the sensitive optical detection systems of current instruments measure subtle changes in bacterial growth. To date, four automated instruments capable of measuring susceptibility to polymyxins are available. Two of them generate overall rapid (4 to 16 h) susceptibility test results (Vitek 2 and Phoenix), while the others (MicroScan and Sensititre) are overnight systems. These systems are associated with computer software to interpret susceptibility results.

(i) **Vitek 2 system.** The Vitek 2 system (bioMérieux) uses plastic reagent cards that contain microliter quantities of antibiotics and test media in wells (84). It tests colistin concentrations ranging from 0.5 to 16  $\mu\text{g/ml}$  and monitors turbidimetry to determine bacterial growth during a period of 4 to 10 h. Compared to dilution methods, the Vitek 2 system displays a low sensitivity for detecting colistin-resistant Gram-negative isolates (83) and is not reliable for detecting heteroresistant subpopulations (76).

(ii) **Phoenix automated microbiology system.** The BD Phoenix automated microbiology system (BD Diagnostics) has a large incubator reader. Panels test colistin concentrations ranging from 0.5 to 4  $\mu\text{g/ml}$ , and the inoculation is manual or automatic (84). MIC results are generated in 6 to 16 h. No study has evaluated the performance of Phoenix for detection of colistin resistance among Gram-negative bacteria. The only published study evaluating polymyxin susceptibility by using the Phoenix system unfortunately did not include colistin-resistant strains (85). Nevertheless, we recently evaluated the accuracy of this system by testing 100 enterobacterial isolates (60 colistin-resistant and 40 colistin-susceptible isolates) and found a high rate (15%) of

false-susceptible results. We observed a low sensitivity for detecting colistin heteroresistance in *K. pneumoniae* and *Enterobacter cloacae* isolates (our unpublished data) but a good sensitivity for detecting plasmid-mediated colistin resistance.

**(iii) MicroScan system.** The MicroScan system (Beckman Coulter Diagnostics) uses microdilution trays with colistin concentrations of 2 and 4  $\mu\text{g/ml}$ . The trays are inoculated manually and incubated in the instrument for 16 to 20 h (84). Compared to dilution methods, the categorical agreement of the MicroScan system is 87% for *Acinetobacter* isolates (86), and the sensitivity is 88% for detection of polymyxin B resistance in *K. pneumoniae* isolates (87).

**(iv) Sensititre system.** The Sensititre system (Thermo Fisher Scientific) is an automated incubation and reading system (84). The tests are standard broth microdilution panels containing prediluted ranges of lyophilized colistin within the wells (0.12 to 128  $\mu\text{g/ml}$ ). Inoculation may be performed by using a Sensititre autoinoculator. Growth is measured after an incubation of 18 to 24 h. A single study has evaluated the Sensititre method, and a 96% categorical agreement with BMD was found, with no false susceptibility results reported (70).

### Impact of Materials on MIC Determination

**Impact of medium.** Polymyxin resistance is regulated by the two-component systems PhoP/PhoQ and PmrA/PmrB (88), which respond to cation (calcium, iron, and magnesium) concentrations and pH variations. These systems are involved in the LPS modifications leading to polymyxin resistance.

There is a high variability of cation concentrations in MH medium depending on the commercial brand, and calcium and magnesium concentrations measured for each brand tested are far below the recommendations of the CLSI (89). This is why the CLSI recommends cation-adjusted MH or supplementation of the culture medium with cations (72, 73).

Iso-Sensitest agar is a well-defined medium with stabilized mineral content that was developed to overcome problems associated with traditional media used for antimicrobial susceptibility tests. Comparison of the agar dilution and Etest methods on MH and Iso-Sensitest agar (76) revealed a lack of detection of the resistant subpopulation of heteroresistant *E. cloacae* isolates for the Etest performed on MH agar, while Iso-Sensitest agar was more sensitive for detecting the resistant subpopulation with both methods (76).

However, a cation-dependent inhibition of antimicrobial activity has been reported for polymyxin antibiotics (90, 91). In fact, it is suspected that the colistin antimicrobial activity might be overestimated if tested using conventional cation-adjusted MH as recommended by the CLSI. Note that the calcium concentration recommended by the CLSI for determining colistin susceptibility *in vitro* is 2-fold higher than the concentration found in human interstitial space fluid *in vivo* (92). A recent study revealed that the MIC of colistin might be misestimated if tested with conventional cation-adjusted growth media (overestimation for *P. aeruginosa* and *A. baumannii* and underestimation for *E. coli*) (92). The use of cation-adjusted or non-cation-adjusted medium therefore remains questionable, and a consensus is still needed.

**Impact of powder composition.** MIC testing is performed using commercially available polymyxin B and colistin sulfate powders. The variability in the relative proportions of the mixture components between powder batches and manufacturers is a potential source of variability of the results (93, 94). In parallel, MICs obtained using BMD with purified forms of the major compounds of polymyxin B were within a  $\log_2$  dilution of the MICs obtained using the U.S. Pharmacopoeia polymyxin B sulfate powder mixture (95). These data suggest that the powder composition may not have an impact on polymyxin susceptibility testing. Note that CMS, as a prodrug, cannot be used for susceptibility testing, as it yields erroneously high MIC values (96).

**Impact of the composition and treatment of plates.** Due to their cationic properties, polymyxins adhere to the negative charges of the microtiter trays commonly used for BMD. Karvanen et al. (97) measured the colistin concentrations following incubation

in polypropylene, polystyrene, and glass tubes. The adsorption was proportionally higher at lower concentrations of the drug. Consequently, the results of colistin BMD measurements significantly differ if tests are conducted in microtiter plates with different coated wells (98). The amount of colistin adsorbed to the plate surface therefore depends on various factors, such as the coating applied to the plate, and is not consistent from well to well (K. Sei, presented at the January 2012 Meeting of the CLSI Subcommittee on Antimicrobial Susceptibility Testing, Tempe, AZ, 22 to 24 January 2012). Since the nature and treatment of plastics are not addressed in the CLSI recommendations, significant variability is observed between laboratories performing the reference BMD method.

**Presence or absence of P-80.** Polysorbate 80 (P-80 or Tween 80) is a surfactant used for the preparation of BMD panels used for susceptibility testing (99). This surfactant has been recommended by the CLSI to prevent or at least mitigate binding of lipoglycopeptides to plastics (72, 73). The presence of 0.002% P-80 mitigates colistin adsorption to polystyrene microplates (Sei, presented at the January 2012 Meeting of the CLSI Subcommittee on Antimicrobial Susceptibility Testing). When P-80 is added to a final concentration of 0.002% in the well, the polymyxin MICs are 4- to 8-fold lower than those obtained without P-80 among isolates with low MICs by BMD testing (70, 99).

It is noteworthy that the effect of P-80 on bacterial viability has not been well evaluated. Also, another concern is that P-80 may act synergistically with polymyxins, consequently giving artificially lower MICs (100). Also, in *P. aeruginosa*, P-80 increases cell permeability and lyses spheroblasts (101). On the other hand, polymyxins destabilize the outer membrane, allowing P-80 to access the inner membrane and induce cell lysis. Therefore, isolates resistant to polymyxins would not be affected significantly by P-80. Therefore, only isolates with polymyxin MICs of  $\leq 1 \mu\text{g/ml}$  might be affected (94).

In January 2014, the CLSI subcommittee decided to pursue a recommendation of polymyxin BMD testing without P-80. However, if a susceptibility breakpoint of  $\leq 1 \mu\text{g/ml}$  is chosen, the ability to detect susceptible isolates without using P-80 may be compromised (94). Since the use of P-80 is still questionable, a solution might be to determine MICs in glass plates, as colistin fixation on glass is less extensive (94). However, glass plates are fragile and expensive.

### Impacts of Subcultures and Storage on MICs

**Impact of subcultures.** A study by Li et al. (26) revealed a loss of colistin resistance when resistant isolates were subcultured without selective pressure. For instance, about 98% of a colistin-resistant *A. baumannii* population lost the resistance phenotype after a single passage in a colistin-free medium.

**Impact of storage.** A loss of colistin resistance was also observed after 6 to 8 months of storage at  $-70^\circ\text{C}$  (70). Among 25 isolates that initially tested resistant by a dilution method, five (20%) tested susceptible by the same method after freezing. The availability of easy, rapid, and inexpensive techniques allowing screening of colistin resistance on fresh cultures in routine laboratories is consequently a real clinical need.

### Interpretive Criteria

There is a lack of consensus between the two organizations setting up breakpoints for polymyxins, namely, the CLSI in the United States (72) and EUCAST in Europe (71). The zone diameter and MIC interpretive criteria given by those two organizations for colistin and polymyxin B are shown in Table 1. However, recent data related to PK suggest that the current breakpoints might be too high (21).

### Quality Controls

Quality control organisms are required during susceptibility testing in order to ensure accuracy and standardization of the procedures. Quality control can be assessed using the *E. coli* ATCC 25922 (NCTC 12241; CIP 76.24) and *P. aeruginosa* ATCC 27853

**TABLE 1** Colistin and polymyxin B breakpoints according to CLSI and EUCAST in 2014

Criteria and bacterial group	Colistin						Polymyxin B					
	Disk content (μg)	Zone diam interpretative criteria (mm) <sup>a</sup>		MIC interpretative criteria (μg/ml) <sup>a</sup>			Disk content (IU)	Zone diam interpretative criteria (mm) <sup>a</sup>		MIC interpretative criteria (μg/ml) <sup>a</sup>		
		Sensitive (S)	Resistant (R)	S	Intermediate (I)	R		S	R	S	I	R
CLSI criteria												
<i>Enterobacteriaceae</i>	—	—	—	—	—	—	300	— <sup>b</sup>	— <sup>b</sup>	—	—	—
<i>Acinetobacter</i> spp.	—	—	—	≤2	—	≥4	—	— <sup>b</sup>	— <sup>b</sup>	≤2	—	≥4
<i>Pseudomonas</i> spp.	10	≥11	≤10	≤2	4	≥8	300	≥12	≤11	≤2	4	≥8
EUCAST criteria												
<i>Enterobacteriaceae</i>	50	≥18 <sup>b,c</sup>	<15 <sup>b,c</sup>	≤2	—	>2	—	— <sup>b</sup>	— <sup>b</sup>	≤2	—	>2
<i>Acinetobacter</i> spp.	—	— <sup>c</sup>	— <sup>c</sup>	≤2	—	>2	—	— <sup>b</sup>	— <sup>b</sup>	≤2	—	>2
<i>Pseudomonas</i> spp.	—	— <sup>c</sup>	— <sup>c</sup>	≤4	—	>4	—	— <sup>b</sup>	— <sup>b</sup>	—	—	—

<sup>a</sup>—, not determined or absent.

<sup>b</sup>Zone diameter interpretative criteria for *Enterobacteriaceae* given by EUCAST are only for veterinary medicine; MIC determination is required for diameters ranging from 15 to 18 mm.

<sup>c</sup>No zone diameter interpretative criteria for human medicine; the MIC must be determined before use.

(NCTC 12903; CIP 76110) reference strains. The disk diffusion and MIC quality control ranges for these strains determined by the CLSI are shown in Table 2 (72).

**Correlation between MICs of Colistin and Polymyxin B**

Despite the high similarity of the molecular structures of colistin and polymyxin B, a recent study including 15,377 Gram-negative bacteria revealed differences between the MICs of colistin and polymyxin B (102). MIC values determined by the Sensititre system were 2-fold higher for polymyxin B than for colistin for 55% and 53% of *Klebsiella* species isolates (*n* = 4,177) and *E. coli* isolates (*n* = 6,311), respectively. However, a categorical agreement of >99% was obtained for enterobacterial strains when breakpoints of ≤2/≥4 for both colistin and polymyxin B were applied. That study showed a high level of agreement between MICs of colistin and polymyxin B for *P. aeruginosa* and *Acinetobacter* spp.

**Qualitative Detection Techniques**

**Rapid detection of heterogeneous populations among colistin-resistant Gram-negative bacteria by use of capillary electrophoresis.** Sautrey et al. (103) proposed a capillary electrophoresis method for rapid detection of heterogeneous populations of colistin-resistant strains. However, further development is required for such applications to be used in clinical laboratories on a daily basis.

**Rapid detection of colistin-resistant *A. baumannii* isolates by use of the Micromax assay.** The Micromax assay is based on the detection of released nucleotides, indicating cell wall damage, in the presence of colistin (104). After incubation with 0.5 μg/ml of colistin, strains are considered resistant to colistin if ≤11% of bacteria present cell wall damage. Bacteria are incubated for 90 min in Mueller-Hinton broth to achieve exponential growth and then incubated for 60 min with colistin at concentrations of 0 and 0.5 μg/ml, respectively. Bacteria embedded in agarose are incubated with a lysis solution removing only weakened cell walls. The released fragmented DNA may be stained with the fluorochrome SYBR gold (Molecular Probes, Eugene, OR) and visualized by fluorescence microscopy (45 min to 60 min of technical processing and scoring under the microscope). This method is faster than the routine automatic microdilution

**TABLE 2** Zone diameter and MIC quality control ranges for polymyxins according to CLSI guidelines

Strain	Zone diam (mm) range		MIC (μg/ml) range	
	Colistin	Polymyxin B	Colistin	Polymyxin B
<i>E. coli</i> ATCC 25922	11–17	13–19	0.25–2	0.25–2
<i>P. aeruginosa</i> ATCC 27853	11–17	14–18	0.5–4	0.5–2

procedure (3 h 30 min versus 6 to 8 h) and is accurate for detecting colistin resistance in *A. baumannii* (100% sensitivity and 96% specificity). Another advantage is that it can be automated. However, the manual task and the cost of the materials (fluorochrome and epifluorescence microscope) are disadvantages for its routine use.

**Rapid detection of colistin-resistant *Enterobacteriaceae* isolates by use of the Rapid Polymyxin NP test.** We developed the Rapid Polymyxin NP test, which is based on the detection of bacterial growth in the presence of a defined polymyxin concentration (105). Detection is based on detection of glucose metabolism upon bacterial growth. Glucose metabolism induces the formation of acid, leading to a color change of the red phenol used as a pH indicator. The test is performed with a final concentration of bacteria of ca.  $10^8$  CFU/ml in each well (or tube), and the final concentration of polymyxin is 3.75  $\mu$ g/ml. Visual inspection of the tray is made after 10 min and then every hour for 2 h. The test is considered positive (indicating polymyxin resistance) if the isolate grows in the presence of colistin (color change from orange to yellow), while it is considered negative (indicating polymyxin susceptibility) if the isolate does not grow in the presence of polymyxin (no color change). This test is rapid (less than 2 h) and easy to perform.

By testing a total of 200 enterobacterial isolates exhibiting either resistance (intrinsic or acquired, or various) or susceptibility to polymyxins, the specificity and sensitivity of this test were evaluated at 99.3% and 95.4%, respectively, compared to BMD as the reference method (105). Note that the Rapid Polymyxin NP test identified the isolates exhibiting a heteroresistance phenotype as well as those producing the plasmid-mediated MCR-1 determinant (see below).

For the Rapid Polymyxin NP test, the adequate culture media for culturing the bacteria prior to the test were Mueller-Hinton agar, Luria-Bertani agar, Columbia agar plus 5% sheep blood, chocolate agar, UriSelect 4 agar, and eosin methylene blue agar.

The Rapid Polymyxin NP test may also detect colistin-resistant *Enterobacteriaceae* directly from blood cultures (106). Results are obtained within 4 h.

**Selective medium.** So far, no selective medium allowing screening for any type of polymyxin-resistant Gram-negative isolates (with intrinsic, chromosomally encoded, or plasmid-mediated polymyxin resistance) has been available. Neither commercial nor in-house screening culture media had been designed that might permit screening of patients possibly colonized by polymyxin-resistant isolates. Therefore, we developed SuperPolymyxin, a selective culture medium for detection of any type of polymyxin-resistant Gram-negative organism (107). The SuperPolymyxin medium prevents swarming of *Proteus* spp. (intrinsically resistant to polymyxins) and also the growth of Gram-positive bacteria and fungi, by addition of daptomycin and amphotericin B, respectively. Its base corresponds to the eosin methylene blue medium (Levine's medium) (108) selective for Gram-negative bacteria, which differentiates lactose fermenters (black colonies) from nonfermenters (colorless or light lavender colonies). In addition, differentiation of lactose fermenters is also possible to some extent. The SuperPolymyxin medium contains a colistin concentration (3.5  $\mu$ g/ml) that allows clear categorization between polymyxin-resistant and -susceptible isolates. The sensitivity and specificity of this medium have been found to be 100% (107).

## Genotypic Methods

Although the mechanisms underlying resistance to polymyxins have not all been elucidated, acquisition of colistin resistance in Gram-negative bacteria has been attributed to lipopolysaccharide (LPS) modifications via diverse routes, including (i) the addition of cationic groups to the LPS reducing the overall negative charge of the LPS and consequently preventing the fixation of polymyxins; (ii) loss of the LPS and, consequently, loss of the polymyxin target; (iii) the overproduction of capsule polysaccharide (CPS) hiding polymyxin binding sites; and (iv) the release of CPS trapping polymyxins. Specific modifications of outer membrane porins and overexpression of efflux pump systems have also been described (88).

Several molecular mechanisms have been associated with colistin resistance in Gram-negative bacteria, such as alterations in the PmrA/PmrB, PhoP/PhoQ, ParR/ParS, ColR/ColS, and CprR/CprS two-component systems and alterations in the *mgrB* gene, which encodes a negative regulator of PhoPQ. Mutations leading to the addition of cationic groups on lipid A result in a less anionic lipid A and, consequently, to less fixation of polymyxins (88).

Similarly, alterations in the *lpxA*, *lpxC*, and *lpxD* genes of *A. baumannii* result in inactivation of lipid A biosynthesis, leading to a complete loss of LPS and, consequently, to a loss of the polymyxin target (109).

The mechanisms of polymyxin resistance can be identified by sequencing those specific genes. However, molecular techniques cannot be envisioned in the near future considering that (i) many chromosomally encoded mechanisms of resistance remain to be identified, (ii) it is difficult to extrapolate whether some substitutions identified in proteins known to be involved in LPS biosynthesis lead to resistance, and (iii) the levels of expression of the corresponding genes may vary and consequently influence the level of resistance to polymyxins.

There is an exception that corresponds to the recent identification of the plasmid-borne *mcr-1/mcr-2* genes, whose products confer resistance to polymyxins (see below). According to the current knowledge on the topic, identification of these genes may be considered a signature of resistance or reduced susceptibility to polymyxins. This is why identifying the gene makes sense in this case, since qualitative genetic results may be translated directly into a nonsusceptibility phenotype. Screening of both *mcr-1* and *mcr-2* can be performed by using a standard PCR protocol using the primers MCR-1/2-Fw (5'-TAT CGC TAT GTG CTA AAG CC-3') and MCR-1/2-Rv (5'-TCT TGG TAT TTG GCG GTA TC-3'), giving rise to a 715-bp amplicon. Also, a SYBR green-based real-time PCR assay that provides a simple, specific, sensitive, and rapid molecular tool for detection of *mcr-1*-positive isolates was recently published (110). That technique was validated on human and animal isolates and may be applied to extensive surveillance studies.

Porin mutations and overexpression of efflux pump systems may also be involved in colistin resistance (88), and it is very likely that phenotypic resistance to polymyxins in clinical isolates often results from combined resistance mechanisms (e.g., defects in outer membrane proteins combined with structural modification of the LPS). Phenotypic methods, such as the Rapid Polymyxin NP test, are consequently very relevant for determining the subsequent therapeutic decision, since they actually concretely determine the susceptibility or lack thereof of isolates, in contrast to genotypic methods, which detect only potential resistance and require sequencing of multiple genes.

## RESISTANCE MECHANISMS IN ENTEROBACTERIACEAE


### Intrinsic Resistance Mechanisms in *Proteus mirabilis* and *Serratia marcescens*

In *P. mirabilis* and *S. marcescens*, naturally occurring resistance to polymyxins is linked to the constitutive expression of the *arnBCADTEF* operon and/or the *eptB* gene, causing addition of phosphoethanolamine (pEtN) and/or 4-amino-4-deoxy-L-arabinose (L-Ara4N) cationic groups to the LPS. This modification increases the charge of the LPS, which is the initial target of the polymyxins, and therefore decreases polymyxin binding, giving rise to intrinsic resistance of these species (111–113).

### Mechanisms Responsible for Acquired Resistance in *Enterobacteriaceae*

Acquired resistance to polymyxins has been identified in several genera of the *Enterobacteriaceae*, such as *Klebsiella*, *Escherichia*, *Enterobacter*, and *Salmonella*. Colistin resistance mechanisms remain unknown for some bacterial species, but several molecular mechanisms have been identified. The most common is modification of the LPS via cationic substitution, similar to that observed in bacteria with intrinsic resistance to polymyxins. A single transferable mechanism of resistance has been identified so far (see below), with most of the resistance mechanisms being encoded chromosomally.





**FIG 3** Regulation pathways of LPS modifications in *Klebsiella pneumoniae*.

Similar to what is observed in strains that are naturally resistant to colistin, addition of cationic groups (L-Ara4N and pEtN) to the LPS is responsible for acquisition of colistin resistance in *Enterobacteriaceae*. A large panel of genes and operons are involved in qualitative modification of the LPS (Fig. 3), including genes and operons coding for enzymes that are directly involved in LPS modifications (genes responsible for synthesis of cationic groups and/or their addition to the LPS), i.e., the *pmrC* gene, the *pmrE* gene, and the *pmrHFUJKLM* operon; regulatory genes, such as those encoding proteins involved in the PmrAB and PhoPQ two-component systems; and the regulators of these two-component systems, i.e., the *mgrB* gene, which negatively regulates the PhoPQ system, and the newly described *crrAB* two-component regulatory system, which regulates the PmrAB system.

**Genes encoding LPS-modifying enzymes. (i) The *pmrC* gene.** The *pmrCAB* operon codes for three proteins, namely, the phosphoethanolamine (pEtN) phosphotransferase PmrC, the response regulator PmrA (also called BasR), and the sensor kinase protein PmrB (also called BasS) (114). The phosphoethanolamine phosphotransferase PmrC adds a pEtN group to the LPS (Fig. 3) (114).

**(ii) The *pmrHFUJKLM* operon and the *pmrE* gene.** The *pmrHFUJKLM* operon (also called the *arnBCADTEF* or *pbgPE* operon) codes for a total of seven proteins (115). The *pmrE* gene and the *pmrHFUJKLM* operon are responsible for the synthesis of the L-aminoarabinose group (L-Ara4N) and its fixation to lipid A (Fig. 3) (115).

**(iii) The *pmrA* and *pmrB* genes, which encode the PmrAB two-component system.** Environmental stimuli, such as macrophage phagosomes, ferric ( $\text{Fe}^{3+}$ ) iron, aluminum ( $\text{Al}^{3+}$ ), and low pH (e.g., pH 5.5), mediate activation of PmrB through its periplasmic domain (114). The PmrAB and PhoPQ two-component systems are normally activated when bacteria are phagocytized into macrophages, allowing bacterial survival (114).

PmrB is a protein with tyrosine kinase activity that activates PmrA by phosphorylation. PmrA in turn activates the transcription of the *pmrCAB* operon, the *pmrHFUJKLM* operon, and the *pmrE* gene involved in LPS modification (pEtN and L-Ara4N addition) (Fig. 3) (114).

Specific mutations within the *pmrA* and *pmrB* genes have been described as being responsible for acquired colistin resistance in *K. pneumoniae* (105, 116–120), *Enterobac-*

*ter aerogenes* (121), and *Salmonella enterica* (122, 123) (Table 3). These mutations are responsible for constitutive activation of the PmrAB two-component system, leading to upregulation of the *pmrCAB* operon, the *pmrHFJKLM* operon, and the *pmrE* gene, and thus to the synthesis of pEtN and L-Ara4N and their transfer to lipid A (Fig. 3).

Some polymorphism in the *pmrAB* genes of colistin-resistant *E. coli* has been reported (124, 125), but the involvement of these mutations in the colistin resistance phenotype has not formally been demonstrated, since no complementation or site-directed mutagenesis has been performed.

**(iv) The *phoP* and *phoQ* genes, which encode the PhoPQ two-component system.** The *phoPQ* operon codes for two proteins, namely, the regulator protein PhoP and the sensor protein kinase PhoQ. Environmental stimuli, such as macrophage phagosomes, low magnesium ( $Mg^{2+}$ ), and low pH (e.g., pH 5.5), mediate activation of PhoQ through its periplasmic domain (114). The PhoPQ two-component system allows the expression of genes that code for magnesium transport, enzymes that modify the LPS to allow resistance to cationic antimicrobial peptides, and enzymes that decrease the cell stress caused by acidic pH or some virulence factors (126, 127). The PhoPQ two-component system therefore allows bacterial survival under conditions of low magnesium or acidic pH or in the presence of cationic antimicrobial peptides.

PhoQ is a protein with tyrosine kinase activity that activates PhoP by phosphorylation. PhoP in turn activates the transcription of the *pmrHFJKLM* operon, involved in the addition of L-Ara4N to the LPS (Fig. 3) (126, 127). PhoP can also activate the PmrA protein, either directly or indirectly via the PmrD connector protein, causing the addition of pEtN to the LPS.

Several mutations in the *phoP* and *phoQ* genes are responsible for acquired resistance to polymyxins in *K. pneumoniae* (81, 105, 117, 118, 120, 128) (Table 3). One mutation potentially involved in colistin resistance in *E. coli* has also been described (65). These mutations are responsible for constitutive activation of the PhoPQ two-component system, leading to upregulation of the *pmrHFJKLM* operon and thus to the synthesis of L-Ara4N and its transfer to lipid A (Fig. 3).

### Regulators of the PmrAB and PhoPQ Two-Component Systems

**The *mgrB* gene.** MgrB (also called YobG) is a small transmembrane protein of 47 amino acids (129). Upon activation of PhoP, the *mgrB* gene is upregulated. The MgrB protein in turn represses the expression of the PhoQ-encoding gene, leading to negative regulation of the PhoPQ two-component system (Fig. 3) (129). Inactivation of the *mgrB* gene (the negative regulator of the PhoPQ two-component system) leads to overexpression of the *phoPQ* operon, thus causing *pmrHFJKLM* operon activation, leading to the production of L-Ara4N responsible for the acquisition of colistin resistance.

Several missense mutations resulting in amino acid substitutions and nonsense mutations and therefore leading to a truncated MgrB protein may be responsible for acquired resistance to colistin in *K. pneumoniae* (Table 3). Other alterations, such as insertions or deletions of small nucleotide sequences in the *mgrB* gene, or even some complete deletions of the *mgrB* locus, have been reported (120, 130, 131). Insertional inactivation caused by diverse insertion sequences (IS), belonging to several families and inserted at different locations within the *mgrB* gene, is often responsible for acquired resistance to colistin in *K. pneumoniae* (105, 117, 120, 130–132) and *Klebsiella oxytoca* (133, 134). Recently, the transposition of genes encoding extended-spectrum  $\beta$ -lactamases (ESBLs) or carbapenemases, leading to disruption of the chromosomal *mgrB* gene, was reported as a source of resistance to colistin (135, 136). Notably, selective pressure with  $\beta$ -lactams leading to the acquisition of  $\beta$ -lactamase genes may therefore be responsible for coselection of colistin resistance. Despite the high homology observed among *mgrB* gene sequences of *Enterobacteriaceae* organisms (129), disruption of this gene has so far not been found to be responsible for acquired resistance to colistin in genera other than *Klebsiella*.

**The *crrAB* operon.** The *crrAB* (colistin resistance regulation) operon codes for two proteins, namely, the regulatory protein CrrA and the sensor protein kinase CrrB. The

**TABLE 3** Chromosomal mutations and amino acid deletions responsible for acquired colistin resistance in *Klebsiella pneumoniae*, *Enterobacter aerogenes*, *Escherichia coli*, *Salmonella enterica*, *P. aeruginosa*, and *A. baumannii* isolates

Bacterial group and species	Protein (normal length [aa])	Domain involved (residues) <sup>a,b</sup>	Amino acid change <sup>d</sup>	Reference(s)
<i>Enterobacteriaceae</i>				
<i>K. pneumoniae</i>	PmrA (223)	REC (1–112)	S42N	120
			G53C	105, 120
			G53S	105
	PmrB (365)	Trans_reg_C (145–216) TM (13–35) HAMP (90–142) HisKA (143–203)	ΔR14	118
			L17Q	105
			L82R	116
			S85R	120
			T140P	120
			T157P	117–119
			S208N	118
			ΔY209	118
			R256G	117
			V3F	117
	PhoP (223)	HATPase_c (250–358) REC (1–112)	L26Q	120
			S86L	117
			D191Y	81
	PhoQ (488)	Trans_reg_C (145–220) PhoQ sensor (10–189) HAMP (195–263) HisKA (267–330)	R16C	105
			L26P	117
			L96P	120
			D150G	117
			S174N	118
			V258F	117
			L348Q	120
			G385S	120
			D434N	128
			K3*	105
	MgrB (47)	HATPase_c (375–482)	L9*	120
			I13*	120
			A14S	120
			W20R	105
			L24H	130
			V26*	120
			M27K	105
			C28F	120
			C28Y	117, 120, 128, 130
			C28*	105, 120
			Q30*	105, 120
			D31N	120
			Q33*	105
			F35I	120
			G37S	130
			C39Y	105
			N42Y/K43I	105
			I45T	105
			W47R	105
			W47*	105
	*48Y	117		
	CrrB (353)	TM (12–34) HAMP (81–135) HisKA (136–200)	Q10L	128, 137
			Y31H	137
			L94 M	128
			W140R	137
			N141I	137
			P151S	137
			S195N	137
			G53S	121
R81S <sup>c</sup>			125	
Δ7–12 <sup>c</sup>			124	
<i>E. aerogenes</i> <i>E. coli</i>	PmrA (222)	REC (1–112) Trans_reg_C (145–216)		
<i>E. coli</i>	PmrB (363)	TM1 (15–37) TM2 (69–91)		

(Continued on next page)

**TABLE 3** (Continued)

Bacterial group and species	Protein (normal length [aa])	Domain involved (residues) <sup>a,b</sup>	Amino acid change <sup>d</sup>	Reference(s)			
<i>S. enterica</i>		HAMP (92–144)					
		HisKA (145–205)	T156K <sup>c</sup>	124			
			A159V <sup>c</sup>	124			
	PhoP (223)			V161G <sup>c</sup>	125		
			HATPase_c (252–360)				
			PhoQ_sensor (10–189)				
			HAMP (195–263)				
			HisKA (267–330)				
			REC (1–112)				
			Trans_reg_C (145–220)				
			PhoQ (486)	PhoQ_sensor (10–189)			
				HAMP (195–263)			
				HisKA (267–330)			
	PmrA (222)		HATPase_c (374–480)	E375K <sup>c</sup>	65		
			REC (1–112)	G15R <sup>c</sup>	123		
				G53E <sup>c</sup>	123		
				G53R <sup>c</sup>	123		
				R81C <sup>c</sup>	123		
				R81H <sup>c</sup>	123		
			PmrB (356)		Trans_reg_C (145–216)		
					TM (13–35)	Δ11–14 <sup>c</sup>	122
						L14F <sup>c</sup>	123
						L14S <sup>c</sup>	123
						M15L <sup>c</sup>	122
						L22P <sup>c</sup>	123
		S29R <sup>c</sup>			123		
	HAMP (89–141)	T92A <sup>c</sup>			123		
		P94Q <sup>c</sup>			123		
		E121A <sup>c</sup>			123		
				S124P <sup>c</sup>	123		
				N130Y <sup>c</sup>	123		
			HisKA (142–202)	T147P <sup>c</sup>	123		
			R155P <sup>c</sup>	123			
			T156M <sup>c</sup>	123			
			T156P <sup>c</sup>	123			
			V161G <sup>c</sup>	123			
			V161L <sup>c</sup>	123			
			V161M <sup>c</sup>	123			
			E166K <sup>c</sup>	123			
		HATPase_c (249–356)	M186I <sup>c</sup>	123			
			G206R <sup>c</sup>	123			
			G206W <sup>c</sup>	123			
		S305R <sup>c</sup>	123				
Nonfermentative bacilli <i>P. aeruginosa</i>	PmrA (221)	REC (1–112)					
		Trans_reg_C (145–216)	L157Q	166			
	PmrB (477)			L14P	167		
			TM1 (15–37)				
			PD (38–160)	ΔD45	74, 167		
				A54V	167		
			TM2 (161–183)	L167P	166		
			HAMP (186–238)	G188D	167		
				F237L	118		
			HisKA (239–304)	L243Q	167		
				A247T	168		
				A248V	167		
		S257N	167				
	PhoQ (448)			M292I	167		
				M292T	169		
			HATPase_c (348–459)				
				R6C	170		
				TM1 (7–29)			

(Continued on next page)

**TABLE 3** (Continued)

Bacterial group and species	Protein (normal length [aa])	Domain involved (residues) <sup>a,b</sup>	Amino acid change <sup>d</sup>	Reference(s)			
<i>A. baumannii</i>	PD (30–166)		ΔV57–Q332	170			
			N104I	118			
			K123Q	166			
			K123E	118			
			Q133E	118			
			A143V	166			
			V152*	168			
			TM2 (167–189)		V184G	118	
					A207R	118	
					R214H	118	
					H223R	168	
			HisKA (238–300)		V260G	163, 247	
					ΔL364–G365	170	
			HATPase_c (343–448)		I421*	170	
					Fr at I421	170	
	D433*	170					
	R444C	170					
	ParR (235)	REC (7–117)			L18I	118	
					N24S	118	
					S24N	118	
					M59I	171	
					E156K	171	
	ParS (428)	Trans_reg_C (152–228)			L14Q	171	
			PD (28–131)	V101 M	171		
			TM2 (132–154)	L137P	171		
			HAMP (155–207)				
			HisKA (208–273)	Q232E	118		
			HATPase_c (318–428)	G361R	118		
			H398R	247			
	ColS		A106V	172			
			R241C	172			
	CprS	REC (2–112)	E8D	177, 180			
			M12I	174			
			P102H	173			
			S119T	174			
			PmrA (224)	Trans_reg_C (150–221)	TM1 (10–29)	T13N	173
					S14L	175	
					S17R	177	
					Fr at F26	176	
					ΔA32–E35	174	
			PD (30–141)		D64V	174	
	A80V	174					
	L87F	175					
	Y116H	177					
	I121F	178					
TM2 (142–164)		M145K			175		
		ΔL160			174		
		P170L			174, 179		
		P170Q			174		
		A183T			178		
		A184V			178		
		P190S			178		
HisKA (218–280)		T192I			178		
		L208F			174		
		A226V			174		
		A227V	173, 175, 176				
		Q228P	178				
		R231L	174				
		T232I	177				
		P233S	118, 173–176, 179				
		P233T	173				
		T235I	174				
N256I	174						

(Continued on next page)

TABLE 3 (Continued)

Bacterial group and species	Protein (normal length [aa])	Domain involved (residues) <sup>a,b</sup>	Amino acid change <sup>d</sup>	Reference(s)
			A262P	173
			R263C	174
			R263L	177
			R263P	174
			Q277H	174
			G315D	174
		HATPase_c (326–437)	N353Y	175
			P377L	174
			F387Y	175
			S403F	175
	LpxA (262)		Fr at I25	109
			G68D	109
			Q72K	109
			Fr at H121	109
			Fr at D130	109
			H159D	109
			Q234*	109
	LpxC (276)		P30L	109
			Fr at D45	109
			Fr at T285	109
	LpxD (356)		Fr at K317	109

<sup>a</sup>Domains predicted in SMART by using protein sequences of *Escherichia coli* K-12 substrain MG1655, *Klebsiella pneumoniae* subsp. *pneumoniae* MGH 78578, *Salmonella enterica* serovar Typhimurium LT2, *P. aeruginosa* PAO1, and *A. baumannii* AB0057. REC, CheY-homologous receiver domain; Trans\_reg\_C, transcriptional regulatory protein, C-terminal domain; TM, transmembrane domain; TM1, first transmembrane domain; TM2, second transmembrane domain; PD, periplasmic domain; HAMP, histidine kinases, adenyl cyclases, methyl-binding proteins, and phosphatases; HisKA, histidine kinase A (phosphoacceptor) domain; HATPase\_c, histidine kinase-like ATPases; PhoQ sensor, phosphorelay signal transduction system.

<sup>b</sup>A periplasmic domain (PD) was not predicted in SMART but was assumed to be between TM1 and TM2.

<sup>c</sup>The involvement of the mutation in the colistin resistance profile was determined by *in silico* analysis.

<sup>d</sup>Δ, deletion; Fr, frameshift; \*, stop codon.

physiological role of the *crrAB* operon is still unknown. However, inactivation of the *crrB* gene leads to overexpression of the *pmrAB* operon, thus causing activation of the *pmrHFJKLM* operon and of the *pmrC* and *pmrE* genes, consequently leading to the production of L-Ara4N and pEtN, both of which are responsible for the acquisition of colistin resistance (Fig. 3) (128). CrrB inactivation may also modify lipid A through activation of a glycosyltransferase-like protein (128).

Six amino acid substitutions in the CrrB protein have been identified as being responsible for acquired resistance to polymyxins in *K. pneumoniae* (Table 3) (128, 137).

### The Intrinsic Regulator RamA

The intrinsic regulator RamA of *K. pneumoniae* is known to play a significant role in the overall response to antimicrobials. It regulates genes that are linked to permeability barriers and therefore may be involved in reduced susceptibility to antibiotics. It was recently shown that increased levels of this regulator caused LPS alterations and consequently reduced susceptibility to polymyxins (138).

### Plasmid-Mediated Resistance to Polymyxins

The plasmid-mediated *mcr-1* gene, responsible for horizontal transfer of colistin resistance, was described first for *E. coli* and *K. pneumoniae* isolates recovered in China between 2011 and 2014 (139). The encoded MCR-1 protein is a member of the phosphoethanolamine transferase enzyme family, as its acquisition results in the addition of phosphoethanolamine to lipid A, and consequently in a more cationic LPS, similarly to the chromosomal mutations mentioned above.

Overall, production of MCR-1 in *E. coli* leads to 4- to 8-fold increases of the MICs of polymyxins. Therefore, without additional resistance mechanisms, production of MCR-1 is enough to confer resistance to colistin in *E. coli* and other enterobacterial species, such as

*K. pneumoniae* (our unpublished data). Note that despite the fact that polymyxins actually share the same mechanism of action as that of the cationic antimicrobial peptides (CAMPs) cathelicidin LL-37,  $\alpha$ -defensin 5 (HD5), and  $\beta$ -defensin 3 (HDB3), which are normal components of the immune system, coresistance to CAMPs and polymyxins has not been observed (J. Dobias, L. Poirel, and P. Nordmann, submitted for publication).


Apart from resistance to polymyxin antibiotics, production of MCR-1 was shown to confer resistance to lysozyme (140). The structure of MCR-1 was recently solved at a 1.32-Å resolution, revealing that its active site is similar to that of related phosphoethanolamine transferases (141). Threonine 285 was identified as the putative nucleophile for catalysis, as it was phosphorylated in the catalytic domain of MCR-1 (cMCR-1). Four zinc ions were identified in the active site of cMCR-1, which is thus a metalloenzyme. The binding sites for the lipid A and phosphatidylethanolamine substrates were not apparent in the cMCR-1 structure, likely indicating that they were present in the membrane domain.

Following these initial findings, the *mcr-1* gene was reported worldwide and beyond China, on all continents (Fig. 4; Table 4). The earliest *mcr-1*-positive strain was collected from chickens in China 3 decades ago (142), when colistin first started to be used in food-producing animals. The *mcr-1* gene has been found in various genera of the *Enterobacteriaceae* (*Escherichia*, *Klebsiella*, *Enterobacter*, *Cronobacter*, *Salmonella*, *Shigella*, and *Kluyvera*) isolated from the environment, vegetable and meat foods, animals, and human beings (Fig. 4; Table 4). Note that the occurrence of MCR-1-producing *E. coli* in the environment in Switzerland but also in Asian imported vegetables in the same country highlights the likely wide occurrence of that resistance trait in many different environments (143).

The hypothesis that animals, particularly pigs and cattle, might be a main source of MCR-1 producers is very strong. Indeed, several features are in accordance with such a hypothesis, including the high selective pressure in veterinary practice and the wide occurrence of that resistance trait in isolates recovered from animals (144).

The genetics of acquisition of the *mcr-1* gene has been investigated extensively. This gene was found in plasmids possessing various backbones (IncI2, IncHI2, IncP, IncX4, IncFI, and IncFIB) and of various sizes (58 to 251 kb). Upstream of the *mcr-1* gene, the IS*Apl1* insertion sequence element is inconstantly identified (Table 4) (139). Thanh et al. (145) described an *mcr-1* gene disrupted by a 22-bp duplication in a *Shigella sonnei* isolate. This isolate was colistin susceptible, but under selective pressure with colistin, one copy of the 22-bp tandem repeat could be deleted, restoring the open reading frame of *mcr-1* and leading to colistin resistance. This deactivated version of the colistin resistance gene *mcr-1* suggests a fitness cost for the active *mcr-1* gene. Some but not all plasmids bearing the *mcr-1* gene carry other antimicrobial resistance genes encoding resistance to clinically relevant antibiotics for human medicine, such as  $\beta$ -lactams, aminoglycosides, quinolones, fosfomycin, sulfonamides, and tetracyclines. The location of the *mcr-1* gene on multidrug resistance plasmids is worrying because the use of antimicrobials other than polymyxins can participate in the coselection of isolates carrying *mcr-1* and in their spread. More worryingly, the plasmid-mediated *mcr-1* gene has been identified in highly drug-resistant *Enterobacteriaceae* isolates harboring plasmids encoding carbapenemase genes (*bla*<sub>NDM-1</sub>, *bla*<sub>NDM-5</sub>, *bla*<sub>NDM-9</sub>, *bla*<sub>OXA-48</sub>, *bla*<sub>KPC-2</sub>, and *bla*<sub>VIM-1</sub>) (146–152). Note that the *mcr-1* gene was recently identified on the chromosome of an *E. coli* strain in Switzerland, suggesting that this resistance gene might be integrated and therefore stabilized in the genome in some isolates (153).

Further investigations are required to better understand the process of acquisition of the *mcr-1* gene; however, we recently showed that it was located within a 2,600-bp genetic structure, defined as the “*mcr-1* cassette,” that might have been mobilized by transposition (154). The cassette was found to carry its own promoter sequences driving the expression of *mcr-1*. In addition, it was shown that several isolates may possess the *mcr-1* gene located in a composite transposon structure made of two copies of IS*Apl1* (155). However, that structure has not been identified systematically, and therefore further investigations are still required to better understand the process



**FIG 4** Reports of MCR-1-producing isolates in humans, animals, and both humans and animals.

of acquisition of that gene from an unknown progenitor in plasmids replicating in *Enterobacteriaceae*.

MCR-1-producing enterobacterial isolates have often been identified as colonizers in either humans or animals. Nevertheless, there are some reported cases of infections, including two patients with bacteremia in Switzerland (156).

A functional variant of *mcr-1* (Q3L) encoding MCR-1.2 was detected in KPC-3-producing *K. pneumoniae* in Italy (157), likely sharing the same activity as MCR-1.

In addition, the plasmid-mediated colistin resistance gene *mcr-2* was identified in *E. coli* strains recovered from piglets in Belgium (158). It shared 77% nucleotide identity with *mcr-1* and was carried on an IncX4 plasmid.

**Other Mechanisms Contributing to Polymyxin Resistance in *Enterobacteriaceae***

**Hyperproduction of CPS.** A study showed that the capsule polysaccharide (CPS) acts as a protective barrier against polymyxins in *K. pneumoniae* (159). The upregulation



**TABLE 4** Worldwide reports of *Enterobacteriaceae* isolates harboring a plasmid-mediated *mcr-1* gene

Species	Plasmid features <sup>a</sup>									
	Country of isolation	Country of origin or traveled region	Sample origin	Period (yr)	Inc type	Size (kb)	Mobile element	Other antimicrobial resistance(s)	Reference(s)	
<i>E. coli</i>	China	China	Chickens	1980–2014	—	—	—	—	142	
	China	China	Human (fecal carriage)	Before 2011	—	—	—	—	218, 219	
	China	China	Chickens, pigs, and humans (infections)	2011–2014	IncI2	64	ISApI1	No	139	
	China	China	—	2011–2014	IncHI2	251	ISApI1	Resistance to cefotaxime ( <i>bla</i> <sub>CTX-M-14b</sub> ), aminoglycosides, florfenicol, olaquinox, cotrimoxazole, fosfomycin ( <i>fosA3</i> ), and ciprofloxacin ( <i>oqxAB</i> )	220	
	China	China	Chicken meat	2014	IncI2	65	—	—	146	
	China	China	Human (blood)	2014–2015	—	—	—	—	147	
	China	China	Human (fecal carriage)	2015	—	—	—	—	221	
	China	USA	Human (fecal carriage)	2016	IncFI	33	—	Resistance to β-lactams ( <i>bla</i> <sub>CTX-M-15</sub> and <i>bla</i> <sub>TEM-1</sub> )	148	
	Laos	Laos	Human (fecal carriage) and pigs	2012	—	—	—	—	222	
	Thailand	Thailand	Human (fecal carriage)	2012	—	—	—	—	223	
	Vietnam	Vietnam	Pigs (fecal carriage)	2014–2015	—	—	ISApI1	Resistance to cefotaxime ( <i>bla</i> <sub>CTX-M-55b</sub> ), trimethoprim ( <i>dfrA12</i> ), tetracycline ( <i>tetA</i> ), aminoglycosides [ <i>aadA3</i> , <i>aph(3')-I</i> ], phenicol ( <i>cmiA1</i> ), quinolones ( <i>qnrS1</i> , <i>oqxA</i> ), lincosamides [ <i>inu(F)</i> ], and sulfonamides ( <i>sul2</i> , <i>sul3</i> )	224	
	Cambodia	Cambodia	Human (feces)	2012	—	—	ISApI1	—	224	
	Malaysia	Malaysia	Water, chickens, pigs	2013	—	—	ISApI1 or not	—	225	
	Japan	Japan	Cattle (mastitis)	2008–2013	IncI2	60–61	—	—	226	
	France	France	Veal calves (feces)	2005–2014	IncHI2	—	—	Resistance to cefotaxime ( <i>bla</i> <sub>CTX-M-1</sub> ), sulfonamides, and tetracyclines	227	
	France	France	Broiler, turkeys, pigs	2007–2014	—	—	—	—	228	
	Italy	Italy	Human (urine, surgical wound)	2013–2015	—	—	—	—	229	
	Italy	Italy	Human (rectal swabs)	2015	NT	35	—	—	230	
	United Kingdom	United Kingdom or Egypt	Human (blood, stools)	2012–2015	IncHI2, IncI2	—	ISApI1 or not	—	231	
	Switzerland	—	River water	2012	—	—	—	—	143	
	Switzerland	Thailand and Vietnam	Vegetables	2014	—	—	—	—	143	
	Switzerland	Switzerland	Human (urinary tract infection)	2015	—	60	—	Resistance to chloramphenicol, florfenicol, and cotrimoxazole	149	
	Switzerland	Switzerland	Human (blood)	2016	IncFIB	30 and 80	—	—	156	
Belgium	Belgium	Calves and piglets (feces)	2011–2012	IncP	80	Truncated ISApI1	Resistance to trimethoprim ( <i>dfrA1</i> ), tetracycline ( <i>tetA</i> ), aminoglycosides [ <i>aadA1</i> , <i>aph6-Id/strA</i> , and <i>aph(3')-Ib/strB</i> ], and sulfonamides ( <i>sul1</i> )	223		
Netherlands	Europe	Chicken meat	2009–2014	—	—	—	—	232		
Netherlands	Netherlands	Chickens, veal calves, turkeys	2010–2015	—	—	—	—	233		
Netherlands	Dutch fresh meat and imported frozen meat	Retail meat (mostly chicken and turkey)	2009–2016	—	—	—	—	233		
Netherlands	Netherlands	Human (blood)	2011	—	—	—	—	233		

(Continued on following page)

TABLE 4 (Continued)

Species	Plasmid features <sup>a</sup>					Reference(s)			
	Country of isolation	Country of origin or traveled region	Sample origin	Period (yr)	Inc type		Size (kb)	Mobile element	Other antimicrobial resistance(s)
	Netherlands	Travel in Tunisia, South America, China, Southeast Asia	Human (fecal carriage)	2012–2013	—	—	—	—	234
	Netherlands	Germany	Veal valves, broilers, and turkey	2010–2015	IncH12 or IncX4	—	ISAp11	—	235
	Germany		Pigs and human (wound infection)	2010–2015	IncH12 or IncX4	—	ISAp11 or not	—	150
	Denmark	Europe	Chicken meat	2012–2014	IncI2 or IncX4	—	—	—	236
	Denmark	Denmark	Human (bloodstream infection)	2015	IncI2	—	—	—	236
	Canada	Unknown	Beef meat	2010	IncH12A	—	—	—	151
	Canada	Lived in Egypt for 5 years	Human (gastrostomy site and rectum)	2011	IncI2	—	—	—	151
	USA	USA	Human (urine)	2016	IncF	225	ISAp11	Resistance to β-lactams ( <i>bla</i> <sub>CTX-M-55</sub> )	237
	Algeria	Algeria	Chickens	2015	—	—	—	—	222
	Tunisia	Tunisia/France	Chickens	2015	IncH12	—	—	Resistance to β-lactams ( <i>bla</i> <sub>CTX-M-1</sub> )	238
	Egypt	Egypt	Human (sputum)	2015	—	>90	—	—	239
	South Africa	South Africa	Human	2014–2015	IncI2	65, 70	ISAp11 or not	—	154
					IncH12	150	—	—	154
					IncX4	30	—	—	154
	South Africa	South Africa	Broiler chicken	2008–2014	IncI2	62	ISAp11	—	240
	Brazil	Brazil	Chicken, swine	2003–2015	—	—	—	—	241
	China	China	Human (surgical wound, peritoneal fluid)	2015	—	—	—	—	147
	China	China	Food animals and human (infections)	2011–2014	IncI2	64	ISAp11	No	139
	Denmark	Denmark	Human (unknown)	2014	—	—	—	—	224
	China	China	Human (urine)	2014	IncF1	70	—	—	242
	China	China	Human (vaginal secretion)	2014	IncF1	65	—	Resistance to β-lactams ( <i>bla</i> <sub>TEM-1</sub> and <i>bla</i> <sub>CTX-M-15</sub> )	242
	China	China	Chicken (diarrhea)	2015	IncI2	65	ISAp11	—	152
	Portugal	Portugal	Food animals	2011	IncH12	—	ISAp11	—	218, 225, 243
	Japan	Japan	Swine (septicemia)	2013	IncI2	58	—	—	226
	France	France	Chicken meat, guinea fowl pie	2012	IncX4	—	—	—	244
	France	France	Pork sausage	2013	IncP	—	—	—	244
	France	France	Broilers	2013	IncP	—	—	—	244
	United Kingdom	United Kingdom	Human (feces)	2012–2015	IncH12, IncX4	—	No	—	231
	United Kingdom	Travel in Asia and United Arab Emirates	Human (feces)	2012–2015	IncH12, IncI2	—	ISAp11 or not	—	231
	Netherlands	—	Chicken meat	2010–2015	IncX4	30	—	—	235
	Netherlands	—	Turkey meat	2013	IncX4	30	—	—	235
	Netherlands	—	Turkey meat	2015	IncX4	30	—	—	235
	United-Kingdom	Europe	Poultry meat	2012–2015	IncH12	—	No	—	231
	Vietnam	Vietnam	Human (feces)	2008	IncI2	—	—	—	145
	China	China	Hospital sewage	2015	IncI2	57	—	—	216

<sup>a</sup>NT, nontypeable; —, unknown.

of capsular biosynthesis genes indeed reduces the interactions of polymyxins with the bacterial surface, leading to polymyxin resistance.

*K. pneumoniae* is able to release anionic capsular polysaccharides from its surface (160). This release leads to the trapping of cationic antimicrobial peptides, such as polymyxins, thus decreasing the amount of antibiotic reaching the bacterial surface. The CPS is connected to the bacterial surface through an ionic interaction with the LPS, and this interaction is stabilized by divalent cations (161). As a consequence, the release of CPS in the presence of polymyxins is likely due to perturbation of the cation-dependent bridges between the molecules of LPS.

**Role of porins.** It has been shown that a periplasmic protein (Ydel) regulated by the PhoPQ and PmrAB two-component systems can interact with the OmpD porin to increase bacterial resistance to polymyxins in *Salmonella enterica* (162).

**Role of efflux pumps.** The role of efflux in colistin resistance is not well understood, but several studies suggested the involvement of efflux pumps in colistin resistance. Mutations in *kpnEF* and *acrAB*, encoding components of efflux pumps, may actually lead to a 2-fold decrease of the MIC of colistin and increase bacterial survival in the presence of a low concentration of polymyxins (163, 164). Addition to the test medium of low doses of the efflux pump inhibitor carbonyl cyanide *m*-chlorophenylhydrazone (CCCP) decreased the MICs for resistant strains (128- to 512-fold reductions) and partially or completely inhibited the regrowth of resistant subpopulations (165). However, this observation should be considered with caution owing to the nonspecific effect of CCCP on efflux systems, with a likely wider impact on bacterial metabolism.

### **Mechanisms of Polymyxin Resistance in *Pseudomonas aeruginosa* and *Acinetobacter baumannii***

***Pseudomonas aeruginosa.*** The colistin resistance in *P. aeruginosa* is mediated by five two-component systems that regulate LPS modifications. As for the *Enterobacteriaceae*, alterations in the PmrAB (74, 118, 166–169) and PhoPQ (118, 166, 168, 170) two-component systems have been shown to be responsible for acquired resistance to colistin. Mutations in these two-component systems cause constitutive alterations and consequently activate transcription of the *pmrHFJKLM* operon and the subsequent addition of L-Ara4N to the LPS, finally leading to colistin resistance. Notably, unlike what is observed in *K. pneumoniae*, the colistin resistance mediated by PhoPQ modifications does not depend on the PmrAB system.

Three other two-component systems have been proved to contribute to colistin resistance in *P. aeruginosa*, namely, ParRS, ColRS, and CprRS. The ParRS (polymyxin adaptive resistance) two-component system is involved in adaptative resistance to polymyxins (118, 166, 171). Mutations in this system cause constitutive expression of the *pmrHFJKLM* operon and thus lead to the addition of L-Ara4N to the LPS, leading to colistin resistance. Additionally, mutations in the ColRS and CprRS two-component regulatory systems may also contribute to polymyxin resistance, since the association of mutations in the *phoQ* gene and mutations in the *colS* or *cprS* gene confers a high level of colistin resistance (172). The action of the ColRS and CprRS systems may occur through the activation of the *phoQ* gene and/or through other genes that have not yet been identified.

***Acinetobacter baumannii.*** The main mechanism of colistin resistance in *A. baumannii* corresponds to the addition of cationic groups to the LPS (qualitative modification of the LPS); nevertheless, acquired resistance to colistin may also be the consequence of a complete loss of LPS production (quantitative modification of the LPS).

The addition of cationic groups in *A. baumannii* is mediated by mutations in PmrAB (118, 173–180). Mutations in the *pmrA* and *pmrB* genes have been shown to cause colistin resistance through upregulation of the *pmrCAB* operon, leading to pEtN synthesis but not to L-Ara4N synthesis (unlike in *Enterobacteriaceae*).

The second mechanism of colistin resistance in *A. baumannii* corresponds to the complete loss of LPS caused by alterations of the lipid A biosynthesis genes, namely, the *lpxA*, *lpxC*, and *lpxD* genes. Mutations identified in those genes were either

substitutions, truncations, frameshifts (109), or insertional inactivation by the insertion sequence IS*Aba11* (181).

## EPIDEMIOLOGY OF RESISTANCE TO POLYMYXINS

### General Epidemiology of Resistance to Polymyxins

Although polymyxins currently retain significant *in vitro* activity against most Gram-negative organisms, resistance to these antibiotics is increasingly being reported among clinical isolates (29, 182).

The SENTRY antimicrobial surveillance program carried out a worldwide survey in 2009 and reported low rates of resistance to polymyxins among Gram-negative pathogens (*Acinetobacter* spp., *P. aeruginosa*, *E. coli*, and *Klebsiella* spp.) (<0.1% to 1.5%) (183). However, a rising trend was observed in a 2006-2009 study period focusing on *K. pneumoniae* isolates (resistance rates of 1.2% in 2006 and 1.8% in 2009), probably because of the extensive and/or inadequate usage of polymyxins worldwide for treating infections with MDR Gram-negative bacteria.

Colistin resistance in *K. pneumoniae* represents a growing public health concern, since this bacterial species is one of the main pathogens of nosocomial infection and has gathered a wide range of resistance mechanisms to broad-spectrum antibiotics over the years. Table 5 shows the populations studied (mainly carbapenem-resistant *K. pneumoniae* [CR-KP] clinical isolates), along with the methods that have been used to determine the rate of colistin resistance, since some methods are now known to underestimate the level of colistin resistance and therefore may significantly bias the proposed rates. The occurrence of colistin resistance in *K. pneumoniae* has been reported in surveillance studies and clinical case reports worldwide (Table 5) (183). Many studies report an increase of the resistance rate among multidrug-resistant *K. pneumoniae* isolates, particularly among CR-KP isolates, with high colistin resistance rates reported (Table 5). More worryingly, multiple outbreaks with carbapenem- and colistin-resistant isolates have been reported in North America and Europe (Table 6; Fig. 5).

**North America.** Multicenter surveys showed low rates of resistance among *K. pneumoniae* isolates in Canada (2.9%) (184) and the United States (4%) (185) (Table 5). However, the colistin resistance rate was higher (6.7 to 18%) among carbapenemase-producing isolates (185-187). In addition, outbreaks with colistin-resistant, KPC-producing *K. pneumoniae*, mostly attributed to the international epidemic clone type ST258, have been reported in the United States (188, 189) and Mexico (190) (Table 6; Fig. 5).

**South America.** The results from the SENTRY antimicrobial surveillance program showed a moderate resistance rate in Latin America in 2009 (3%) (183); however, the emergence of colistin-resistant *K. pneumoniae* isolates has been reported in Argentina (191), Colombia (119), and Brazil (87).

**Europe.** Multiple outbreaks of both carbapenem- and colistin-resistant *K. pneumoniae* isolates have been reported in Europe (Table 6; Fig. 5). Outbreaks with KPC-producing *K. pneumoniae* isolates attributed to the international epidemic clone type ST258 have been reported in the Netherlands (192), Hungary (193), Greece (194, 195), and Italy (196, 197).

In addition to the two outbreaks attributed to the ST258 clone (196, 197), a large nosocomial outbreak of colistin-resistant and KPC-producing ST512 *K. pneumoniae* isolates was reported in Italy (198) (Table 6; Fig. 5). More worryingly, colistin resistance was recently reported at a high level (>20%) among carbapenemase-producing isolates in ICUs of two Italian hospitals (199, 200), with an even higher rate (36.1%) in hospitals in Rome (68) (Table 6). Moreover, a national study reported a countrywide level of colistin resistance among KPC-producing *K. pneumoniae* isolates, with 43% of isolates being resistant to colistin (201) (Table 5).

In Greece, several outbreaks caused by KPC-producing, colistin-resistant *K. pneumoniae* isolates have been reported (194, 195) (Table 6; Fig. 5). Studies performed in two Greek hospitals reported a huge increase in colistin resistance within a few years (<3.5% incidence before 2010 and >20% incidence after 2010) (202, 203).

**TABLE 5** Studies reporting prevalences of colistin resistance among *K. pneumoniae* clinical isolates<sup>d</sup>

Study type and period	Country	Setting	Test method	Total no. of isolates	Carbapenemase producers (no. [%])	Polymyxin-resistant isolates (no. [%])	Reference(s)
Studies reporting colistin resistance rates among overall clinical isolates							
2006–2009	Worldwide	Worldwide surveillance	BMD	9,774	NA	(1.5)	183
2007–2008	Canada	National	BMD	515	NA	15 (2.9)	184
2013–2014	United States	Multicenter	BMD	1,205	NA	(4)	185
2006–2007	South Korea	Multicenter (9 hospitals)	BMD	221 <sup>a</sup>	15 (13.3)	24 (10.9) <sup>b</sup>	206
2004–2005	Singapore	Single center	Agar dilution	16	NA	1 (6)	207
Studies reporting colistin resistance rates among CR-KP isolates							
2008–2011	Canada	Multicenter	Etest	30	30 (100)	2 (6.7)	184, 186
2013–2014	United States	Multicenter	BMD	69	69 (100)	(18) <sup>c</sup>	185
2003–2004	United States	Multicenter	BMD or agar dilution	96	96 (100)	(9)	187
2010–2013	Greece	Single center (only ICU)	Vitek2, Etest	92	92 (100)	20 (21.7)	202
2010	Greece	Single center	Vitek2, Etest	120	120 (100)	25 (20.8)	203
2014	Italy	Single center (only ICU)	Vitek2, Etest	214	214 (100)	47 (21.9)	199
2013	Italy	Single center (only ICU)	BMD	25	24 (100)	6 (24.0)	200
2013–2014	Italy	National	BMD	178	178 (100)	76 (43)	201
2010–2011	Italy	Multicenter (9 hospitals)	Vitek2, BMD	97	97 (100)	35 (36.1)	68
2010–2012	Spain	Hospital	Agar dilution	79	79 (100)	18 (22.8)	204
2014	France	National	BMD	561	561 (100)	35 (6.2)	205
2012–2013	Turkey	Single center	Vitek2, Etest	37	36 (98)	(2.7)	245
2006–2007	Israel	Single center	?	88	88 (100)	(4.5)	246
2009–2010	China	Single center	Agar dilution	68	68 (100)	3 (4.4)	208
2012	Taiwan	National	Sensititre	247	55 (22.3)	(12.1)	209

<sup>a</sup>Isolated from blood samples.

<sup>b</sup>Number of colistin-resistant isolates according to EUCAST breakpoints.

<sup>c</sup>Eighteen percent colistin resistance among 4 *E. coli* and 69 *K. pneumoniae* isolates harboring carbapenemases.

<sup>d</sup>NA, not applicable.

**TABLE 6** Studies reporting outbreaks of colistin-resistant and carbapenemase-producing isolates<sup>e</sup>

Study period	Country	Setting	Test method	Colistin MIC (μg/ml)	Resistance mechanism	Total no. of cases	Beta-lactamase(s)	Sequence type	Reference
2010	United States	One single hospital (ICU and medical ward)	Agar dilution	>128	ND	5	KPC-2	ST258	188
2009	United States	Two hospitals and a long-term acute care setting in Detroit, MI	Etest	8–64	ND	4	KPC	ND	189
2012–2013	Mexico	One single hospital in Mexico City	BMD	4	ND	15	KPC-2	ST258	190
2013	Netherlands	One hospital and a nursing home	Vitek2, Etest	ND	ND	6	KPC-2, SHV-12	ST258	192
2008–2009	Hungary	Three hospitals in Miskolc	Etest	16–32	ND	8	KPC-2, SHV-12, TEM-1, SHV-11	ST258	193
2008	Greece	ICUs of two distinct hospitals	Etest	12–128	ND	6	KPC-2, SHV-12	ST258	194
2004–2005	Greece	One single hospital in Athens (ICU)	Etest	12 → 1,024	ND	13 (multiclinal)	ND	ND	195
2010	Italy	Two hospitals in Catania, Sicily	BMD	8–64	ND	8	KPC-3, SHV-11, TEM-1, OXA-9	ST258	196
2011	Italy	One single hospital in Palermo, Sicily	Etest		ND	28 (multiclinal) <sup>a</sup>			197
				3–128	ND	24	KPC-3, SHV-11, TEM-1, OXA-9	ST258	
				3–32	ND	3	KPC-3, SHV-12, TEM-1	ST273	
				4–12	ND	2	KPC-3, SHV-28, TEM-1, CTX-M-15	ST15	
2010–2013	Italy	One single hospital (22 different wards)	Vitek2, Sensititre	4 → 16	<i>mgrB</i> Δnt109/119	Multiclinal <sup>b</sup>			198
					Unknown <sup>c</sup>	50	KPC-3	ST512	
					Unknown <sup>c</sup>	5	KPC-3	ST512	
						2	KPC-2	ST101	
2010–2012	Spain	One hospital	Agar dilution	ND	ND	14	VIM-1	ST22	204
2014	France	Hospital in Picardie	BMD	4–64	Unknown <sup>d</sup>	15	OXA-48, CTX-M-15	ST11	205


<sup>a</sup>One patient with two colistin-resistant clones (belonging to ST-258 and ST-273).

<sup>b</sup>There was a total of 93 bloodstream infections, but only isolates recovered in 2013 were investigated further.

<sup>c</sup>No mutation in the *mgrB*, *pmrA*, or *pmrB* gene was responsible for colistin resistance.

<sup>d</sup>No mutation in the *mgrB* gene was responsible for colistin resistance.

<sup>e</sup>ND, not determined.



**FIG 5** Outbreaks caused by colistin-resistant, carbapenemase-producing *K. pneumoniae* isolates. Each star indicates a single report.

During a 2-year period (2010 to 2012) in Spain, a study showed an increase of the prevalence of colistin resistance among carbapenemase-producing *K. pneumoniae* isolates, from 13.5 to 31.7%, and an outbreak of colistin-resistant, VIM-1-producing *K. pneumoniae* was reported (204).

In France, a national survey revealed a low rate of colistin resistance (6.2%) among carbapenemase-producing *K. pneumoniae* isolates; nevertheless, an outbreak of OXA-48 carbapenemase-producing and colistin-resistant *K. pneumoniae* isolates was reported (205).

**Middle East.** In Turkey and Israel, low rates of resistance to colistin among CR-KP isolates have been reported (2.7% and 4.5%, respectively). However, multiclonal outbreaks with OXA-48-, NDM-, and both OXA-48- and NDM-producing *K. pneumoniae* are currently ongoing in Turkey (our unpublished data).

**Africa.** A very low colistin resistance rate was reported among *K. pneumoniae* isolates in Tunisia (1.2%), but this rate was probably underestimated because susceptibility to colistin was primarily screened using a DD method generating high false susceptibility rates (205). The emergence of colistin resistance was reported for *K. pneumoniae* isolates recovered in South Africa (81, 119) and Nigeria (120).

**Asia.** Moderate rates of colistin resistance (about 6 to 11%) have been reported for *K. pneumoniae* isolates from South Korea (206) and Singapore (207), and similar resistance rates (4.4 to 12.1%) were found among CR-KP isolates in China (208) and Taiwan (209). Colistin-resistant *K. pneumoniae* isolates have also been reported in Laos and Thailand (120).

### Risk Factors

The use of colistin was found to be an independent risk factor for the occurrence of resistance in Gram-negative bacteria (210, 211). Important increases of colistin resistance rates among ESBL-producing *K. pneumoniae* isolates (from 0 to 71% and from 11.1 to 75%) were reported after the introduction of selective digestive tract decontamination in two intensive care units (212, 213). Moreover, this decontamination failed to prevent colonization by ESBL-producing *Enterobacteriaceae*, and such a strategy should be abandoned. Note that the inappropriate use of colistin (such as suboptimal dosing or prolonged monotherapy) has been shown to be a source of colistin resistance selection (214, 215). The occurrence of colistin resistance in *P. aeruginosa* was most

effectively prevented by 8-h dosing intervals compared to 12- or 24-h dosing intervals (45).

### Specific Epidemiology of the Plasmid-Mediated *mcr-1* Resistance Gene

Notably, plasmid-borne resistance to polymyxins has been reported for few different enterobacterial species so far, mainly among *E. coli* isolates and rarely for *Salmonella enterica*, *Enterobacter* spp., and *K. pneumoniae*. There are also some scattered reports of MCR-1-producing isolates in other species, such as *Cronobacter sakazakii* (152) and *Kluyvera ascorbata* (216). According to the current literature on the subject, the distribution of MCR-1 appears to be worldwide, covering all continents (217). It remains to be determined if the identification of the *mcr-1* gene worldwide corresponds to subsequent spread from an original source (China?) or to simultaneous gene mobilization events in different parts of the world. Ongoing epidemiological surveys should provide some important clues.

It is actually speculated that the original source of the gene, or at least of its mobilization and emergence, might be the animal world. This speculation is based on the fact that MCR-1-producing *E. coli* isolates have been identified in several animals and animal food products, including chickens and chicken meat, pigs and piglets, cattle, calves, and turkeys, but also in humans (Fig. 4). The corresponding samples were collected from many Asian countries (Cambodia, China, Japan, Laos, Malaysia, Taiwan, Singapore, and Vietnam) but also from Europe (Belgium, Denmark, France, Germany, Portugal, Italy, the Netherlands, Spain, Sweden, Switzerland, and the UK), the Americas (Argentina, Brazil, and Canada), and Africa (Algeria, Egypt, South Africa, and Tunisia) (Table 4). Note that a study conducted in Switzerland identified MCR-1-producing *E. coli* isolates in vegetables imported from Asia (143), and positive isolates were also identified in environmental water samples in Switzerland and Malaysia (Table 4).

The speculation of an animal origin of the *mcr-1* gene is also based on genetic features, since this gene is often associated with the insertion sequence *ISAp11*, identified in *Pasteurella multocida*, which is a common animal pathogen, and also with the *bla*<sub>CMY-2</sub> and *florR* genes, which are often identified in animal enterobacterial isolates (144). Finally, another feature suggesting an animal source of the problem is the heavy usage of polymyxins in veterinary medicine, with usage on many different animal species.

Dating the emergence of MCR-1-positive strains remains quite difficult; however, a Chinese study retrospectively identified positive isolates recovered from chickens during the 1980s (142), and they were discovered as early as 2005 in veal calves in France (144). It therefore seems that the emergence of MCR-positive isolates, at least in animals, is not a recent event. Very likely, there has been some silent dissemination of that resistance mechanism throughout the last few decades, and the current situation shows an ongoing further dissemination rather than an emerging phenomenon.

### CONCLUSIONS

Polymyxins are gaining increasing interest because of the current epidemiological situation, with MDR Gram-negative bacteria spreading worldwide and with a paucity of novel marketed antibiotics. In some areas where infections caused by carbapenem-resistant *Enterobacteriaceae* are now common (such as Greece or Italy), the use of polymyxins (alone or often in combination with other antibiotics) is becoming crucial and may even be considered first-line therapy. The reevaluation of some critical issues in relation to polymyxins (accurate susceptibility testing, defining correct breakpoints, and better appreciating the toxicity issues) now opens new perspectives for its use. Studies that may permit a better evaluation of the PK-PD data, the toxicity level, and appropriate drug combinations are therefore crucial.

The recent identification of plasmid-mediated mechanisms of resistance to polymyxins also modifies the perspective. Indeed, epidemiological studies have to be initiated in order to better evaluate the extent of dissemination of this resistance in human and veterinary medicine and the impact of its occurrence. The perspective of



nosocomial dissemination of MDR Gram-negative organisms possessing resistance determinants to all main antibiotics is frightening, in particular for *K. pneumoniae*, which is one of the main nosocomial pathogens. Whether veterinary medicine is affecting the epidemiological situation by providing selective pressure with polymyxins has to be precisely determined. Whether discontinuing some specific usages of these drugs (prophylaxis or metaphylaxis in animals and decontamination of MDR bacteria in humans) should be considered is therefore an open debate.

Ultimately, reinforcing the detection of polymyxin-resistant isolates must be encouraged. Prospective epidemiological surveys are needed, since the current knowledge on this issue is very scarce. Actually, the recent development of a rapid diagnostic test for detection of polymyxin resistance, along with the development of a screening agar medium, will contribute to facilitating those surveys.

## ACKNOWLEDGMENTS

This work was funded by the University of Fribourg, Switzerland, and by a grant from the ANIWhA ERA-NET project, Switzerland (ANIWhA).

## REFERENCES

- Benedict RG, Langlykke AF. 1947. Antibiotic activity of *Bacillus polymyxa*. *J Bacteriol* 54:24.
- Hancock RE. 1997. Peptide antibiotics. *Lancet* 349:418–422. [https://doi.org/10.1016/S0140-6736\(97\)80051-7](https://doi.org/10.1016/S0140-6736(97)80051-7).
- Falagas ME, Rafailidis PI, Matthaiou DK. 2010. Resistance to polymyxins: mechanisms, frequency and treatment options. *Drug Resist Updat* 13:132–138. <https://doi.org/10.1016/j.drug.2010.05.002>.
- Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. *Lancet Infect Dis* 6:589–601. [https://doi.org/10.1016/S1473-3099\(06\)70580-1](https://doi.org/10.1016/S1473-3099(06)70580-1).
- Brink AJ, Richards GA, Colombo G, Bortolotti F, Colombo P, Jehl F. 2014. Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics. *Int J Antimicrob Agents* 43:1–6. <https://doi.org/10.1016/j.ijantimicag.2013.06.013>.
- Gallardo-Godoy A, Muldoon C, Becker B, Elliott AG, Lash LH, Huang JX, Butler MS, Pelington R, Kavanagh AM, Ramu S, Phetsang W, Blaskovich MA, Cooper MA. 2016. Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B. *J Med Chem* 59:1068–1077. <https://doi.org/10.1021/acs.jmedchem.5b01593>.
- Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? *Clin Infect Dis* 59:88–94. <https://doi.org/10.1093/cid/ciu213>.
- Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 50:1953–1958. <https://doi.org/10.1128/AAC.00035-06>.
- Barnett M, Bushby SR, Wilkinson S. 1964. Sodium sulphomethyl derivatives of polymyxins. *Br J Pharmacol Chemother* 23:552–574. <https://doi.org/10.1111/j.1476-5381.1964.tb01610.x>.
- Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. 2003. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. *Antimicrob Agents Chemother* 47:1364–1370. <https://doi.org/10.1128/AAC.47.4.1364-1370.2003>.
- Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. *J Antimicrob Chemother* 53:837–840. <https://doi.org/10.1093/jac/dkh167>.
- Dixon RA, Chopra I. 1986. Leakage of periplasmic proteins from *Escherichia coli* mediated by polymyxin B nonapeptide. *Antimicrob Agents Chemother* 29:781–788. <https://doi.org/10.1128/AAC.29.5.781>.
- Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. *Clin Infect Dis* 40:1333–1341. <https://doi.org/10.1086/429323>.
- Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. *Int J Antimicrob Agents* 25:11–25. <https://doi.org/10.1016/j.ijantimicag.2004.10.001>.
- Deris ZZ, Akter J, Sivanesan S, Roberts KD, Thompson PE, Nation RL, Li J, Velkov T. 2013. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. *J Antibiot (Tokyo)* 67:147–151. <https://doi.org/10.1038/ja.2013.111>.
- Bulitta JB, Yang JC, Yohonn L, Ly NS, Brown SV, D'Hondt RE, Jusko WJ, Forrest A, Tsuji BT. 2010. Attenuation of colistin bactericidal activity by high inoculum of *Pseudomonas aeruginosa* characterized by a new mechanism-based population pharmacodynamic model. *Antimicrob Agents Chemother* 54:2051–2062. <https://doi.org/10.1128/AAC.00881-09>.
- Owen RJ, Li J, Nation RL, Spelman D. 2007. In vitro pharmacodynamics of colistin against *Acinetobacter baumannii* clinical isolates. *J Antimicrob Chemother* 59:473–477. <https://doi.org/10.1093/jac/dkl512>.
- Poudyal A, Howden BP, Bell JM, Gao W, Owen RJ, Turnidge JD, Nation RL, Li J. 2008. In vitro pharmacodynamics of colistin against multidrug-resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother* 62:1311–1318. <https://doi.org/10.1093/jac/dkn425>.
- Bergen PJ, Landersdorfer CB, Zhang J, Zhao M, Lee HJ, Nation RL, Li J. 2012. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? *Diagn Microbiol Infect Dis* 74:213–223. <https://doi.org/10.1016/j.diagmicrobio.2012.07.010>.
- Cheah SE, Wang J, Nguyen VTT, Turnidge JD, Li J, Nation RL. 2015. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against *Pseudomonas aeruginosa* and *Acinetobacter baumannii* in mouse thigh and lung infection models: smaller response in lung infection. *J Antimicrob Chemother* 70:3291–3297. <https://doi.org/10.1093/jac/dkv267>.
- Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. *Antimicrob Agents Chemother* 55:3284–3294. <https://doi.org/10.1128/AAC.01733-10>.
- Landersdorfer CB, Nation RL. 2015. Colistin: how should it be dosed for the critically ill? *Semin Respir Crit Care Med* 36:126–135. <https://doi.org/10.1055/s-0034-1398390>.
- Bergen PJ, Li J, Nation RL. 2011. Dosing of colistin—back to basic PK/PD. *Curr Opin Pharmacol* 11:464–469. <https://doi.org/10.1016/j.coph.2011.07.004>.
- Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC. 2003. Synergistic activity of colistin and ceftazidime against multidrug-resistant *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother* 47:905–909. <https://doi.org/10.1128/AAC.47.3.905-909.2003>.
- John EB, Bennett RD, Blaser MJ. 2015. Polymyxins (polymyxin B and colistin), p 549–555. *In* Bennett JE, Dolin R, Blaser MJ (ed), *Mandell*,

- Douglas, and Bennett's principles and practice of infectious diseases, 8th ed. Elsevier/Saunders, Philadelphia, PA.
26. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. 2006. Heteroresistance to colistin in multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 50:2946–2950. <https://doi.org/10.1128/AAC.00103-06>.
  27. Yau W, Owen RJ, Poudyal A, Bell JM, Turnidge JD, Yu HH, Nation RL, Li J. 2009. Colistin hetero-resistance in multidrug-resistant *Acinetobacter baumannii* clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. *J Infect* 58:138–144. <https://doi.org/10.1016/j.jinf.2008.11.002>.
  28. Meletis G, Tzampaz E, Sianou E, Tzavaras I, Sofianou D. 2011. Colistin heteroresistance in carbapenemase-producing *Klebsiella pneumoniae*. *J Antimicrob Chemother* 66:946–947. <https://doi.org/10.1093/jac/dkr007>.
  29. Bialvaei AZ, Samadi Kafil H. 2015. Colistin, mechanisms and prevalence of resistance. *Curr Med Res Opin* 31:707–721. <https://doi.org/10.1185/03007995.2015.1018989>.
  30. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. 1970. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. *Ann Intern Med* 72:857–868.
  31. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18:268–281. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
  32. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012. Colistin: an update on the antibiotic of the 21st century. *Expert Rev Anti Infect Ther* 10:917–934. <https://doi.org/10.1586/eri.12.78>.
  33. Yahav D, Farbman L, Leibovici L, Paul M. 2012. Colistin: new lessons on an old antibiotic. *Clin Microbiol Infect* 18:18–29. <https://doi.org/10.1111/j.1469-0691.2011.03734.x>.
  34. Ortwine JK, Kaye KS, Li J, Pogue JM. 2015. Colistin: understanding and applying recent pharmacokinetic advances. *Pharmacotherapy* 35: 11–16. <https://doi.org/10.1002/phar.1484>.
  35. Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD. 2014. Consistent global approach on reporting of colistin doses to promote safe and effective use. *Clin Infect Dis* 58:139–141. <https://doi.org/10.1093/cid/cit680>.
  36. Theuretzbacher U. 2014. Product information for parenteral colistin varies substantially across Europe. *J Antimicrob Chemother* 69: 1987–1992. <https://doi.org/10.1093/jac/dku064>.
  37. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. *Antimicrob Agents Chemother* 52: 3047–3051. <https://doi.org/10.1128/AAC.00103-08>.
  38. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. *J Chromatogr B Biomed Sci Appl* 761:167–175. [https://doi.org/10.1016/S0378-4347\(01\)00326-7](https://doi.org/10.1016/S0378-4347(01)00326-7).
  39. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. *Antimicrob Agents Chemother* 46:3304–3307. <https://doi.org/10.1128/AAC.46.10.3304-3307.2002>.
  40. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2003. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. *Antimicrob Agents Chemother* 47:1766–1770. <https://doi.org/10.1128/AAC.47.5.1766-1770.2003>.
  41. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE. 2012. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. *Antimicrob Agents Chemother* 56:4241–4249. <https://doi.org/10.1128/AAC.06426-11>.
  42. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, Rafailidis P, Apostolakis H, Baltopoulos G. 2008. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: a prospective, open-label, uncontrolled study. *Clin Ther* 30:143–151. <https://doi.org/10.1016/j.clinthera.2008.01.015>.
  43. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H. 2009. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. *Antimicrob Agents Chemother* 53:3430–3436. <https://doi.org/10.1128/AAC.01361-08>.
  44. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Dodek P, Wood G, Simon D, Peters C, Ahsan M, Chateau D. 2009. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest* 136:1237–1248. <https://doi.org/10.1378/chest.09-0087>.
  45. Bergen PJ, Li J, Nation RL, Turnidge JD, Coulthard K, Milne RW. 2008. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. *J Antimicrob Chemother* 61:636–642. <https://doi.org/10.1093/jac/dkm511>.
  46. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. *Clin Infect Dis* 57:524–531. <https://doi.org/10.1093/cid/cit334>.
  47. Vicari G, Bauer SR, Neuner EA, Lam SW. 2013. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gram-negative bacteremia. *Clin Infect Dis* 56:398–404. <https://doi.org/10.1093/cid/cis909>.
  48. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. 2010. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. *Int J Antimicrob Agents* 35:297–300. <https://doi.org/10.1016/j.ijantimicag.2009.11.016>.
  49. Michalopoulos AS, Falagas ME. 2011. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. *Ann Intensive Care* 1:30. <https://doi.org/10.1186/2110-5820-1-30>.
  50. Roberts JA, Lipman J. 2012. Editorial commentary: closing the loop—a colistin clinical study to confirm dosing recommendations from PK/PD modeling. *Clin Infect Dis* 54:1727–1729. <https://doi.org/10.1093/cid/cis311>.
  51. European Medicines Agency. 2014. European Medicines Agency completes review of polymyxin-based medicines: recommendations issued for safe use in patients with serious infections resistant to standard antibiotics. European Medicines Agency, London, United Kingdom.
  52. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. 2014. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. *Lancet Infect Dis* 14:498–509. [https://doi.org/10.1016/S1473-3099\(14\)70036-2](https://doi.org/10.1016/S1473-3099(14)70036-2).
  53. Lee YJ, Wi YM, Kwon YJ, Kim SR, Chang SH, Cho S. 2015. Association between colistin dose and development of nephrotoxicity. *Crit Care Med* 43:1187–1193. <https://doi.org/10.1097/CCM.0000000000000931>.
  54. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N. 2012. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. *Clin Infect Dis* 54:1720–1726. <https://doi.org/10.1093/cid/cis286>.
  55. Ordoeji Javan A, Shokouhi S, Sahraei Z. 2015. A review on colistin nephrotoxicity. *Eur J Clin Pharmacol* 71:801–810. <https://doi.org/10.1007/s00228-015-1865-4>.
  56. Falagas ME, Kasiakou SK. 2006. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. *Crit Care* 10:R27. <https://doi.org/10.1186/cc3995>.
  57. Sorli L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Alvarez-Lerma F, Knobel H, Benito N, Horcajada JP. 2013. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. *BMC Infect Dis* 13:380. <https://doi.org/10.1186/1471-2334-13-380>.
  58. Bellomo R, Kellum JA, Ronco C. 2007. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. *Intensive Care Med* 33:409–413. <https://doi.org/10.1007/s00134-006-0478-x>.
  59. Akajagbor DS, Wilson SL, Shere-Wolfe KD, Dakum P, Charurat ME, Gilliam BL. 2013. Higher incidence of acute kidney injury with intrave-

- nous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. *Clin Infect Dis* 57:1300–1303. <https://doi.org/10.1093/cid/cit453>.
60. Phe K, Lee Y, McDanel PM, Prasad N, Yin T, Figueroa DA, Musick WL, Cottreau JM, Hu M, Tam VH. 2014. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. *Antimicrob Agents Chemother* 58:2740–2746. <https://doi.org/10.1128/AAC.02476-13>.
  61. Catry B, Cavaleri M, Baptiste K, Grave K, Grein K, Holm A, Jukes H, Liebana E, Navas AL, Mackay D, Magiorakos AP, Romo MA, Moulin G, Madero CM, Pomba MC, Powell M, Pyoralá S, Rantala M, Ruzauskas M, Sanders P, Teale C, Threlfall EJ, Torneke K, van Duijkeren E, Edo JT. 2015. Use of colistin-containing products within the European Union and European Economic Area (EU/EEA): development of resistance in animals and possible impact on human and animal health. *Int J Antimicrob Agents* 46:297–306. <https://doi.org/10.1016/j.ijantimicag.2015.06.005>.
  62. Kempf I, Fleury MA, Drider D, Bruneau M, Sanders P, Chauvin C, Madec JY, Jouy E. 2013. What do we know about resistance to colistin in *Enterobacteriaceae* in avian and pig production in Europe? *Int J Antimicrob Agents* 42:379–383. <https://doi.org/10.1016/j.ijantimicag.2013.06.012>.
  63. Boyen F, Vangroenweghe F, Butaye P, De Graef E, Castryck F, Heylen P, Vanrobaeys M, Haesebrouck F. 2010. Disk prediffusion is a reliable method for testing colistin susceptibility in porcine *E. coli* strains. *Vet Microbiol* 144:359–362. <https://doi.org/10.1016/j.vetmic.2010.01.010>.
  64. Kieffer N, Poirel L, Nordmann P, Madec JY, Haenni M. 2015. Emergence of colistin resistance in *Klebsiella pneumoniae* from veterinary medicine. *J Antimicrob Chemother* 70:1265–1267. <https://doi.org/10.1093/jac/dku485>.
  65. Olaitan AO, Thongmalayvong B, Akkhavong K, Somphavong S, Paboriboune P, Khounsy S, Morand S, Rolain JM. 2015. Clonal transmission of a colistin-resistant *Escherichia coli* from a domesticated pig to a human in Laos. *J Antimicrob Chemother* 70:3402–3404. <https://doi.org/10.1093/jac/dkv252>.
  66. Walsh TR, Wu Y. 2016. China bans colistin as a feed additive for animals. *Lancet Infect Dis* 16:1102–1103. [https://doi.org/10.1016/S1473-3099\(16\)30329-2](https://doi.org/10.1016/S1473-3099(16)30329-2).
  67. European Medicines Agency. 26 May 2016. Updated advice on the use of colistin products in animals within the European Union: development of resistance and possible impact on human and animal health. EMA/231573/2016. [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Scientific\\_guideline/2016/05/WC500207233.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/05/WC500207233.pdf). Accessed 5 September 2016.
  68. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M, Ballardini M, Venditti M, Bordi E, Capozzi D, Balice MP, Tarasi A, Parisi G, Lappa A, Carattoli A, Petrosillo N. 2013. High rate of colistin resistance among patients with carbapenem-resistant *Klebsiella pneumoniae* infection accounts for an excess of mortality. *Clin Microbiol Infect* 19:E23–E30. <https://doi.org/10.1111/1469-0691.12070>.
  69. Landman D, Salamera J, Quale J. 2013. Irreproducible and uninterpretable polymyxin B MICs for *Enterobacter cloacae* and *Enterobacter aerogenes*. *J Clin Microbiol* 51:4106–4111. <https://doi.org/10.1128/JCM.02129-13>.
  70. Hindler JA, Humphries RM. 2013. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. *J Clin Microbiol* 51:1678–1684. <https://doi.org/10.1128/JCM.03385-12>.
  71. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2014. Breakpoint tables for interpretation of MICs and zone diameters, version 2.0. [http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST\\_files/Breakpoint\\_tables/Breakpoint\\_table\\_v\\_2\\_0\\_120221.pdf](http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2_0_120221.pdf).
  72. Clinical and Laboratory Standards Institute (CLSI). 2014. Performance standards for antimicrobial susceptibility testing; 24th informational supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA.
  73. Clinical and Laboratory Standards Institute (CLSI). 2012. Methods for dilution of antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
  74. Schurek KN, Sampaio JL, Kiffer CR, Sinto S, Mendes CM, Hancock RE. 2009. Involvement of *pmrAB* and *phoPQ* in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 53:4345–4351. <https://doi.org/10.1128/AAC.01267-08>.
  75. Behera B, Mathur P, Das A, Kapil A, Gupta B, Bhoi S, Farooque K, Sharma V, Misra MC. 2010. Evaluation of susceptibility testing methods for polymyxin. *Int J Infect Dis* 14:e596–e601. <https://doi.org/10.1016/j.ijid.2009.09.001>.
  76. Lo-Ten-Foe JR, de Smet AM, Diederer BM, Kluytmans JA, van Keulen PH. 2007. Comparative evaluation of the VITEK 2, disk diffusion, Etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant *Enterobacter cloacae* and *Acinetobacter baumannii* strains. *Antimicrob Agents Chemother* 51:3726–3730. <https://doi.org/10.1128/AAC.01406-06>.
  77. Hogardt M, Schmoldt S, Gotzfried M, Adler K, Heesemann J. 2004. Pitfalls of polymyxin antimicrobial susceptibility testing of *Pseudomonas aeruginosa* isolated from cystic fibrosis patients. *J Antimicrob Chemother* 54:1057–1061. <https://doi.org/10.1093/jac/dkh470>.
  78. Moskowitz SM, Garber E, Chen Y, Clock SA, Tabibi S, Miller AK, Doctor M, Saiman L. 2010. Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of *Pseudomonas aeruginosa* and *Stenotrophomonas maltophilia*. *J Antimicrob Chemother* 65:1416–1423. <https://doi.org/10.1093/jac/dkq131>.
  79. Tan TY, Ng LS. 2006. Comparison of three standardized disc susceptibility testing methods for colistin. *J Antimicrob Chemother* 58:864–867. <https://doi.org/10.1093/jac/dkl330>.
  80. Maalej SM, Meziou MR, Rhimi FM, Hammami A. 2011. Comparison of disc diffusion, Etest and agar dilution for susceptibility testing of colistin against *Enterobacteriaceae*. *Lett Appl Microbiol* 53:546–551. <https://doi.org/10.1111/j.1472-765X.2011.03145.x>.
  81. Jayol A, Nordmann P, Brink A, Poirel L. 2015. Heteroresistance to colistin in *Klebsiella pneumoniae* associated with alterations in the PhoPQ regulatory system. *Antimicrob Agents Chemother* 59:2780–2784. <https://doi.org/10.1128/AAC.05055-14>.
  82. Arroyo LA, Garcia-Curiel A, Pachon-Ibanez ME, Llanos AC, Ruiz M, Pachon J, Aznar J. 2005. Reliability of the E-test method for detection of colistin resistance in clinical isolates of *Acinetobacter baumannii*. *J Clin Microbiol* 43:903–905. <https://doi.org/10.1128/JCM.43.2.903-905.2005>.
  83. Tan TY, Ng SY. 2007. Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistin. *Clin Microbiol Infect* 13:541–544. <https://doi.org/10.1111/j.1469-0691.2007.01708.x>.
  84. Jorgensen JH, Ferraro MJ. 2009. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. *Clin Infect Dis* 49:1749–1755. <https://doi.org/10.1086/647952>.
  85. Sinirtas M, Akalin H, Gedikoglu S. 2009. Investigation of colistin sensitivity via three different methods in *Acinetobacter baumannii* isolates with multiple antibiotic resistance. *Int J Infect Dis* 13:e217–e220. <https://doi.org/10.1016/j.ijid.2008.12.012>.
  86. Lee SY, Shin JH, Lee K, Joo MY, Park KH, Shin MG, Suh SP, Ryang DW, Kim SH. 2013. Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of *Acinetobacter* species from a Korean university hospital. *J Clin Microbiol* 51:1924–1926. <https://doi.org/10.1128/JCM.00427-13>.
  87. Perez LR. 2015. Evaluation of polymyxin susceptibility profile among KPC-producing *Klebsiella pneumoniae* using Etest and MicroScan Walk-Away automated system. *APMIS* 123:951–954. <https://doi.org/10.1111/apm.12438>.
  88. Olaitan AO, Morand S, Rolain JM. 2014. Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. *Front Microbiol* 5:643. <https://doi.org/10.3389/fmicb.2014.00643>.
  89. Girardello R, Bispo PJ, Yamanaka TM, Gales AC. 2012. Cation concentration variability of four distinct Mueller-Hinton agar brands influences polymyxin B susceptibility results. *J Clin Microbiol* 50:2414–2418. <https://doi.org/10.1128/JCM.06686-11>.
  90. Chen CC, Feingold DS. 1972. Locus of divalent cation inhibition of the bactericidal action of polymyxin B. *Antimicrob Agents Chemother* 2:331–335. <https://doi.org/10.1128/AAC.2.5.331>.
  91. Newton BA. 1953. Reversal of the antibacterial activity of polymyxin by divalent cations. *Nature* 172:160–161. <https://doi.org/10.1038/172160a0>.
  92. Matzneller P, Strommer S, Osterreicher Z, Mitteregger D, Zeitlinger M. 2015. Target site antimicrobial activity of colistin might be misestimated if tested in conventional growth media. *Eur J Clin Microbiol Infect Dis* 34:1989–1994. <https://doi.org/10.1007/s10096-015-2441-7>.
  93. He J, Ledesma KR, Lam WY, Figueroa DA, Lim TP, Chow DS, Tam VH.

2010. Variability of polymyxin B major components in commercial formulations. *Int J Antimicrob Agents* 35:308–310. <https://doi.org/10.1016/j.ijantimicag.2009.11.005>.
94. Humphries RM. 2015. Susceptibility testing of the polymyxins: where are we now? *Pharmacotherapy* 35:22–27. <https://doi.org/10.1002/phar.1505>.
  95. Tam VH, Cao H, Ledesma KR, Hu M. 2011. In vitro potency of various polymyxin B components. *Antimicrob Agents Chemother* 55:4490–4491. <https://doi.org/10.1128/AAC.00119-11>.
  96. Landman D, Georgescu C, Martin DA, Quale J. 2008. Polymyxins revisited. *Clin Microbiol Rev* 21:449–465. <https://doi.org/10.1128/CMR.00006-08>.
  97. Karvanen MC, Mohamad A, Lagerback P. 2011. Colistin is extensively lost during normal experimental conditions, abstr D-690, p 160. *Abstr 51st Intersci Conf Antimicrob Agents Chemother*. American Society for Microbiology, Washington, DC.
  98. Albur M, Noel A, Bowker K, Macgowan A. 2014. Colistin susceptibility testing: time for a review. *J Antimicrob Chemother* 69:1432–1434. <https://doi.org/10.1093/jac/dkt503>.
  99. Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2012. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. *Diagn Microbiol Infect Dis* 74:412–414. <https://doi.org/10.1016/j.diagmicrobio.2012.08.025>.
  100. Brown MR, Winsley BE. 1968. Synergistic action of polysorbate 80 and polymyxin B sulphate on *Pseudomonas aeruginosa*. *J Gen Microbiol* 50(Suppl):ix.
  101. Brown MR, Geaton EM, Gilbert P. 1979. Additivity of action between polysorbate 80 and polymyxin B towards spheroplasts of *Pseudomonas aeruginosa* NCTC 6750. *J Pharm Pharmacol* 31:168–170. <https://doi.org/10.1111/j.2042-7158.1979.tb13463.x>.
  102. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2015. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. *Diagn Microbiol Infect Dis* 83:379–381. <https://doi.org/10.1016/j.diagmicrobio.2015.08.013>.
  103. Sautrey G, Duval RE, Chevalley A, Fontanay S, Claret I. 2015. Capillary electrophoresis for fast detection of heterogeneous population in colistin-resistant Gram-negative bacteria. *Electrophoresis* 36:2630–2633. <https://doi.org/10.1002/elps.201500064>.
  104. Tamayo M, Santiso R, Otero F, Bou G, Lepe JA, McConnell MJ, Cisneros JM, Gosalvez J, Fernandez JL. 2013. Rapid determination of colistin resistance in clinical strains of *Acinetobacter baumannii* by use of the Micromax assay. *J Clin Microbiol* 51:3675–3682. <https://doi.org/10.1128/JCM.01787-13>.
  105. Nordmann P, Jayol A, Poirel L. 2016. Rapid detection of polymyxin resistance in *Enterobacteriaceae*. *Emerg Infect Dis* 22:1038–1043. <https://doi.org/10.3201/eid2206.151840>.
  106. Jayol A, Dubois V, Poirel L, Nordmann P. 2016. Rapid detection of polymyxin-resistant *Enterobacteriaceae* from blood cultures. *J Clin Microbiol* 54:2273–2277. <https://doi.org/10.1128/JCM.00918-16>.
  107. Nordmann P, Jayol A, Poirel L. 2016. A universal culture medium for screening polymyxin-resistant Gram-negative isolates. *J Clin Microbiol* 54:1395–1399. <https://doi.org/10.1128/JCM.00446-16>.
  108. Levine M. 1943. The effect of concentration of dyes on differentiation of enteric bacteria on eosin-methylene-blue agar. *J Bacteriol* 45:471–475.
  109. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. 2010. Colistin resistance in *Acinetobacter baumannii* is mediated by complete loss of lipopolysaccharide production. *Antimicrob Agents Chemother* 54:4971–4977. <https://doi.org/10.1128/AAC.00834-10>.
  110. Bontron S, Poirel L, Nordmann P. 2016. Real-time PCR for detection of plasmid-mediated polymyxin resistance (*mcr-1*) from cultured bacteria and stools. *J Antimicrob Chemother* 71:2318–2320. <https://doi.org/10.1093/jac/dkw139>.
  111. Aquilini E, Merino S, Knirel YA, Regue M, Tomas JM. 2014. Functional identification of *Proteus mirabilis* *eptC* gene encoding a core lipopolysaccharide phosphoethanolamine transferase. *Int J Mol Sci* 15:6689–6702. <https://doi.org/10.3390/ijms15046689>.
  112. Jiang SS, Liu MC, Teng LJ, Wang WB, Hsueh PR, Liaw SJ. 2010. *Proteus mirabilis* *pmrI*, an RppA-regulated gene necessary for polymyxin B resistance, biofilm formation, and urothelial cell invasion. *Antimicrob Agents Chemother* 54:1564–1571. <https://doi.org/10.1128/AAC.01219-09>.
  113. Lin QY, Tsai YL, Liu MC, Lin WC, Hsueh PR, Liaw SJ. 2014. *Serratia marcescens* *arn*, a PhoP-regulated locus necessary for polymyxin B resistance. *Antimicrob Agents Chemother* 58:5181–5190. <https://doi.org/10.1128/AAC.00013-14>.
  114. Gunn JS. 2008. The *Salmonella* PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. *Trends Microbiol* 16:284–290. <https://doi.org/10.1016/j.tim.2008.03.007>.
  115. Yan A, Guan Z, Raetz CR. 2007. An undecaprenyl phosphate-aminoarabinose flippase required for polymyxin resistance in *Escherichia coli*. *J Biol Chem* 282:36077–36089. <https://doi.org/10.1074/jbc.M706172200>.
  116. Cannatelli A, Di Pilato V, Giani T, Arena F, Ambretti S, Gaibani P, D'Andrea MM, Rossolini GM. 2014. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing *Klebsiella pneumoniae* is associated with low-dosage colistin treatment. *Antimicrob Agents Chemother* 58:4399–4403. <https://doi.org/10.1128/AAC.02555-14>.
  117. Cheng YH, Lin TL, Pan YJ, Wang YP, Lin YT, Wang JT. 2015. Colistin resistance mechanisms in *Klebsiella pneumoniae* strains from Taiwan. *Antimicrob Agents Chemother* 59:2909–2913. <https://doi.org/10.1128/AAC.04763-14>.
  118. Choi MJ, Ko KS. 2014. Mutant prevention concentrations of colistin for *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Klebsiella pneumoniae* clinical isolates. *J Antimicrob Chemother* 69:275–277. <https://doi.org/10.1093/jac/dkt315>.
  119. Jayol A, Poirel L, Brink A, Villegas MV, Yilmaz M, Nordmann P. 2014. Resistance to colistin associated with a single amino acid change in protein PmrB among *Klebsiella pneumoniae* isolates of worldwide origin. *Antimicrob Agents Chemother* 58:4762–4766. <https://doi.org/10.1128/AAC.00084-14>.
  120. Olaitan AO, Diene SM, Kempf M, Berrazeg M, Bakour S, Gupta SK, Thongmalayong B, Akkhavong K, Somphavong S, Paboriboune P, Chairiri K, Komalamisra C, Adelowo OO, Fagade OE, Banjo OA, Oke AJ, Adler A, Assous MV, Morand S, Raoult D, Rolain JM. 2014. Worldwide emergence of colistin resistance in *Klebsiella pneumoniae* from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator *mgrB*: an epidemiological and molecular study. *Int J Antimicrob Agents* 44:500–507. <https://doi.org/10.1016/j.ijantimicag.2014.07.020>.
  121. Diene SM, Merhej V, Henry M, El Filali A, Roux V, Robert C, Azza S, Gavory F, Barbe V, La Scola B, Raoult D, Rolain JM. 2013. The rhizome of the multidrug-resistant *Enterobacter aerogenes* genome reveals how new “killer bugs” are created because of a sympatric lifestyle. *Mol Biol Evol* 30:369–383. <https://doi.org/10.1093/molbev/mss236>.
  122. Olaitan AO, Dia NM, Gautret P, Benkouiten S, Belhouchat K, Drali T, Parola P, Brouqui P, Memish Z, Raoult D, Rolain JM. 2015. Acquisition of extended-spectrum cephalosporin- and colistin-resistant *Salmonella enterica* subsp. *enterica* serotype Newport by pilgrims during Hajj. *Int J Antimicrob Agents* 45:600–604. <https://doi.org/10.1016/j.ijantimicag.2015.01.010>.
  123. Sun S, Negrea A, Rhen M, Andersson DI. 2009. Genetic analysis of colistin resistance in *Salmonella enterica* serovar Typhimurium. *Antimicrob Agents Chemother* 53:2298–2305. <https://doi.org/10.1128/AAC.01016-08>.
  124. Olaitan AO, Morand S, Rolain JM. 2016. Emergence of colistin-resistant bacteria in humans without colistin usage: a new worry and cause for vigilance. *Int J Antimicrob Agents* 47:1–3. <https://doi.org/10.1016/j.ijantimicag.2015.11.009>.
  125. Quesada A, Porrero MC, Tellez S, Palomo G, Garcia M, Dominguez L. 2015. Polymorphism of genes encoding PmrAB in colistin-resistant strains of *Escherichia coli* and *Salmonella enterica* isolated from poultry and swine. *J Antimicrob Chemother* 70:71–74. <https://doi.org/10.1093/jac/dku320>.
  126. Groisman EA. 2001. The pleiotropic two-component regulatory system PhoP-PhoQ. *J Bacteriol* 183:1835–1842. <https://doi.org/10.1128/JB.183.6.1835-1842.2001>.
  127. Park SY, Groisman EA. 2014. Signal-specific temporal response by the *Salmonella* PhoP/PhoQ regulatory system. *Mol Microbiol* 91:135–144. <https://doi.org/10.1111/mmi.12449>.
  128. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, van Duin D, Kaye K, Jacobs MR, Bonomo RA, Adams MD. 2015. Genomic and transcriptomic analyses of colistin-resistant clinical isolates of *Klebsiella pneumoniae* reveal multiple pathways of resistance. *Antimicrob Agents Chemother* 59:536–543. <https://doi.org/10.1128/AAC.04037-14>.
  129. Lippa AM, Goulian M. 2009. Feedback inhibition in the PhoQ/PhoP

- signaling system by a membrane peptide. *PLoS Genet* 5:e1000788. <https://doi.org/10.1371/journal.pgen.1000788>.
130. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F, Conte V, Tryfinopoulou K, Vatopoulos A, Rossolini G. 2014. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing *Klebsiella pneumoniae* of clinical origin. *Antimicrob Agents Chemother* 58:5696–5703. <https://doi.org/10.1128/AAC.03110-14>.
  131. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M, Turkoglu S, Nordmann P. 2015. The *mgrB* gene as a key target for acquired resistance to colistin in *Klebsiella pneumoniae*. *J Antimicrob Chemother* 70:75–80. <https://doi.org/10.1093/jac/dku323>.
  132. Lopez-Camacho E, Gomez-Gil R, Tobes R, Manrique M, Lorenzo M, Galvan B, Salvarelli E, Moatassim Y, Salanueva IJ, Pareja E, Codoner FM, Alvarez-Tejado M, Garcillan-Barcia MP, De la Cruz F, Mingorance J. 2014. Genomic analysis of the emergence and evolution of multidrug resistance during a *Klebsiella pneumoniae* outbreak including carbapenem and colistin resistance. *J Antimicrob Chemother* 69:632–636. <https://doi.org/10.1093/jac/dkt419>.
  133. Jayol A, Poirel L, Villegas MV, Nordmann P. 2015. Modulation of *mgrB* gene expression as a source of colistin resistance in *Klebsiella oxytoca*. *Int J Antimicrob Agents* 46:108–110. <https://doi.org/10.1016/j.ijantimicag.2015.02.015>.
  134. Olaitan AO, Rolain JM. 2015. Interruption of *mgrB* in the mediation of colistin resistance in *Klebsiella oxytoca*. *Int J Antimicrob Agents* 46:354–355. <https://doi.org/10.1016/j.ijantimicag.2015.06.003>.
  135. Jayol A, Nordmann P, Desroches M, Descousser JW, Poirel L. 2016. Acquisition of broad-spectrum cephalosporin resistance leading to colistin resistance in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 60:3199–3201. <https://doi.org/10.1128/AAC.00237-16>.
  136. Zowawi HM, Forde BM, Alfaresi M, Alzarouni A, Farahat Y, Chong TM, Yin WF, Chan KG, Li J, Schembri MA, Beatson SA, Paterson DL. 2015. Stepwise evolution of pandrug-resistance in *Klebsiella pneumoniae*. *Sci Rep* 5:15082. <https://doi.org/10.1038/srep15082>.
  137. Cheng YH, Lin TL, Lin YT, Wang JT. 2016. Amino acid substitutions of CrrB responsible for resistance to colistin through CrrC in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 60:3709–3716. <https://doi.org/10.1128/AAC.00009-16>.
  138. De Majumdar S, Yu J, Fookes M, McAteer SP, Llobet E, Finn S, Spence S, Monahan A, Kissenpennig A, Ingram RJ, Bengoechea J, Gally DL, Fanning S, Elborn JS, Schneiders T. 2015. Elucidation of the RamA regulon in *Klebsiella pneumoniae* reveals a role in LPS regulation. *PLoS Pathog* 11:e1004627. <https://doi.org/10.1371/journal.ppat.1004627>.
  139. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. *Lancet Infect Dis* 16:161–168. [https://doi.org/10.1016/S1473-3099\(15\)00424-7](https://doi.org/10.1016/S1473-3099(15)00424-7).
  140. Sherman EX, Hufnagel DA, Weiss DS. 2016. MCR-1 confers cross-resistance to lysozyme. *Lancet Infect Dis* 16:1226–1227. [https://doi.org/10.1016/S1473-3099\(16\)30395-4](https://doi.org/10.1016/S1473-3099(16)30395-4).
  141. Stojanoski V, Sankaran B, Prasad BV, Poirel L, Nordmann P, Palzkill T. 2016. Structure of the catalytic domain of the colistin resistance enzyme MCR-1. *BMC Biol* 14:81. <https://doi.org/10.1186/s12915-016-0303-0>.
  142. Shen Z, Wang Y, Shen Y, Shen J, Wu C. 2016. Early emergence of *mcr-1* in *Escherichia coli* from food-producing animals. *Lancet Infect Dis* 16:293. [https://doi.org/10.1016/S1473-3099\(16\)00061-X](https://doi.org/10.1016/S1473-3099(16)00061-X).
  143. Zurfluh K, Poirel L, Nordmann P, Nuesch-Inderbinen M, Hachler H, Stephan R. 2016. Occurrence of the plasmid-borne *mcr-1* colistin resistance gene in ESBL-producing *Enterobacteriaceae* in river water and imported vegetable samples in Switzerland. *Antimicrob Agents Chemother* 60:2594–2595. <https://doi.org/10.1128/AAC.00066-16>.
  144. Poirel L, Nordmann P. 2016. Plasmid-encoded colistin resistance: the animal world as the culprit? *J Antimicrob Chemother* 71:2326–2327. <https://doi.org/10.1093/jac/dkw074>.
  145. Thanh DP, Tuyen HT, Nguy T, Nguyen ET, The HC, Wick RR, Thwaites G, Baker S, Holt KE. 2016. Inducible colistin resistance via a disrupted plasmid-borne *mcr-1* gene in a 2008 Vietnamese *Shigella sonnei* isolate. *J Antimicrob Chemother* 71:2314–2317. <https://doi.org/10.1093/jac/dkw173>.
  146. Yao X, Doi Y, Zeng L, Lv L, Liu JH. 2016. Carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing NDM-9 and MCR-1. *Lancet Infect Dis* 16:288–289. [https://doi.org/10.1016/S1473-3099\(16\)00057-8](https://doi.org/10.1016/S1473-3099(16)00057-8).
  147. Du H, Chen L, Tang YW, Kreiswirth BN. 2016. Emergence of the *mcr-1* colistin resistance gene in carbapenem-resistant *Enterobacteriaceae*. *Lancet Infect Dis* 16:287–288. [https://doi.org/10.1016/S1473-3099\(16\)00056-6](https://doi.org/10.1016/S1473-3099(16)00056-6).
  148. Zhong LL, Zhang YF, Doi Y, Huang X, Zhang XF, Zeng KJ, Shen C, Patil S, Xing Y, Zou Y, Tian GB. 2017. Coproduction of MCR-1 and NDM-1 by colistin-resistant *Escherichia coli* isolated from a healthy individual. *Antimicrob Agents Chemother* 61:e01962-16. <https://doi.org/10.1128/AAC.01962-16>.
  149. Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. 2016. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis* 16:281. [https://doi.org/10.1016/S1473-3099\(16\)00006-2](https://doi.org/10.1016/S1473-3099(16)00006-2).
  150. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Kasbohrer A, Roesler U, Michael GB, Schwarz S, Werner G, Kreienbrock L, Chakraborty T. 2016. Colistin resistance gene *mcr-1* in extended-spectrum beta-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis* 16:282–283. [https://doi.org/10.1016/S1473-3099\(16\)00009-8](https://doi.org/10.1016/S1473-3099(16)00009-8).
  151. Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P, Toye B, Irwin R, Melano RG. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:289–290. [https://doi.org/10.1016/S1473-3099\(16\)00067-0](https://doi.org/10.1016/S1473-3099(16)00067-0).
  152. Liu BT, Song FJ, Zou M, Hao ZH, Shan H. 2017. Emergence of colistin resistance gene *mcr-1* in *Cronobacter sakazakii* producing NDM-9 and *Escherichia coli* from the same animal. *Antimicrob Agents Chemother* 61:e01444-16. <https://doi.org/10.1128/AAC.01444-16>.
  153. Zurfluh K, Tasara T, Poirel L, Nordmann P, Stephan R. 2016. Draft genome sequence of *Escherichia coli* S51, a chicken isolate harboring a chromosomally encoded *mcr-1* gene. *Genome Announc* 4:e00796-16. <https://doi.org/10.1128/genomeA.00796-16>.
  154. Poirel L, Kieffer N, Brink A, Coetze J, Jayol A, Nordmann P. 2016. Genetic features of MCR-1-producing colistin-resistant *Escherichia coli* isolates, South Africa. *Antimicrob Agents Chemother* 60:4394–4397. <https://doi.org/10.1128/AAC.00444-16>.
  155. Snesrud E, He S, Chandler M, Dekker JP, Hickman AB, McGann P, Dyda F. 2016. A model for transposition of the colistin resistance gene *mcr-1* by IS*Ap11*. *Antimicrob Agents Chemother* 60:6973–6976. <https://doi.org/10.1128/AAC.01457-16>.
  156. Nordmann P, Lienhard R, Kieffer N, Clerc O, Poirel L. 2016. Plasmid-mediated colistin-resistant *Escherichia coli* in bacteremia in Switzerland. *Clin Infect Dis* 62:1322–1323. <https://doi.org/10.1093/cid/ciw124>.
  157. Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L, Fortunato S, Giani T, Menichetti F, Rossolini GM. 2016. *mcr-1.2*, a new *mcr* variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing *Klebsiella pneumoniae* strain of sequence type 512. *Antimicrob Agents Chemother* 60:5612–5615. <https://doi.org/10.1128/AAC.01075-16>.
  158. Xavier BB, Lammens C, Ruhel R, Kumar-Singh S, Butaye P, Goossens H, Malhotra-Kumar S. 2016. Identification of a novel plasmid-mediated colistin-resistance gene, *mcr-2*, in *Escherichia coli*, Belgium, June 2016. *Euro Surveill* 21:30280. <https://doi.org/10.2807/1560-7917.ES.21.27.30280>.
  159. Campos MA, Vargas MA, Regueiro V, Llopart CM, Alberti S, Bengoechea JA. 2004. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. *Infect Immun* 72:7107–7114. <https://doi.org/10.1128/IAI.72.12.7107-7114.2004>.
  160. Llobet E, Tomas JM, Bengoechea JA. 2008. Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. *Microbiology* 154:3877–3886. <https://doi.org/10.1099/mic.0.2008/022301-0>.
  161. Fresno S, Jimenez N, Izquierdo L, Merino S, Corsaro MM, De Castro C, Parrilli M, Naldi T, Regue M, Tomas JM. 2006. The ionic interaction of *Klebsiella pneumoniae* K2 capsule and core lipopolysaccharide. *Microbiology* 152:1807–1818. <https://doi.org/10.1099/mic.0.28611-0>.
  162. Pilonieta MC, Erickson KD, Ernst RK, Detweiler CS. 2009. A protein important for antimicrobial peptide resistance, Ydel/OmdA, is in the periplasm and interacts with OmpD/NmpC. *J Bacteriol* 191:7243–7252. <https://doi.org/10.1128/JB.00688-09>.
  163. Padilla E, Llobet E, Domenech-Sanchez A, Martinez-Martinez L, Bengoechea JA, Alberti S. 2010. *Klebsiella pneumoniae* AcrAB efflux pump contributes to antimicrobial resistance and virulence. *Antimicrob Agents Chemother* 54:177–183. <https://doi.org/10.1128/AAC.00715-09>.
  164. Srinivasan VB, Rajamohan G. 2013. KpnEF, a new member of the *Klebsiella pneumoniae* cell envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum antimicrobial resis-

- tance. *Antimicrob Agents Chemother* 57:4449–4462. <https://doi.org/10.1128/AAC.02284-12>.
165. Ni W, Li Y, Guan J, Zhao J, Cui J, Wang R, Liu Y. 2016. Effects of efflux pump inhibitors on colistin resistance in multidrug resistant Gram-negative bacteria. *Antimicrob Agents Chemother* 60:3215–3218. <https://doi.org/10.1128/AAC.00248-16>.
  166. Lee JY, Ko KS. 2014. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in *Pseudomonas aeruginosa* clinical isolates. *Diagn Microbiol Infect Dis* 78:271–276. <https://doi.org/10.1016/j.diagmicrobio.2013.11.027>.
  167. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Høiby N. 2012. PmrB mutations promote polymyxin resistance of *Pseudomonas aeruginosa* isolated from colistin-treated cystic fibrosis patients. *Antimicrob Agents Chemother* 56:1019–1030. <https://doi.org/10.1128/AAC.05829-11>.
  168. Barrow K, Kwon DH. 2009. Alterations in two-component regulatory systems of *phoPQ* and *pmrAB* are associated with polymyxin B resistance in clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 53:5150–5154. <https://doi.org/10.1128/AAC.00893-09>.
  169. Abraham N, Kwon DH. 2009. A single amino acid substitution in PmrB is associated with polymyxin B resistance in clinical isolate of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* 298:249–254. <https://doi.org/10.1111/j.1574-6968.2009.01720.x>.
  170. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM. 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of *Pseudomonas aeruginosa* found in colistin-treated cystic fibrosis patients. *Antimicrob Agents Chemother* 55:5761–5769. <https://doi.org/10.1128/AAC.05391-11>.
  171. Muller C, Plesiat P, Jeannot K. 2011. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 55:1211–1221. <https://doi.org/10.1128/AAC.01252-10>.
  172. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM. 2013. Polymyxin resistance of *Pseudomonas aeruginosa* *phoQ* mutants is dependent on additional two-component regulatory systems. *Antimicrob Agents Chemother* 57:2204–2215. <https://doi.org/10.1128/AAC.02353-12>.
  173. Adams MD, Nickel GC, Bajakouszian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA. 2009. Resistance to colistin in *Acinetobacter baumannii* associated with mutations in the PmrAB two-component system. *Antimicrob Agents Chemother* 53:3628–3634. <https://doi.org/10.1128/AAC.00284-09>.
  174. Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. 2011. The *pmrCAB* operon mediates polymyxin resistance in *Acinetobacter baumannii* ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. *Antimicrob Agents Chemother* 55:3743–3751. <https://doi.org/10.1128/AAC.00256-11>.
  175. Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. 2011. Phosphoethanolamine modification of lipid A in colistin-resistant variants of *Acinetobacter baumannii* mediated by the *pmrAB* two-component regulatory system. *Antimicrob Agents Chemother* 55:3370–3379. <https://doi.org/10.1128/AAC.00079-11>.
  176. Kim Y, Bae IK, Lee H, Jeong SH, Yong D, Lee K. 2014. In vivo emergence of colistin resistance in *Acinetobacter baumannii* clinical isolates of sequence type 357 during colistin treatment. *Diagn Microbiol Infect Dis* 79:362–366. <https://doi.org/10.1016/j.diagmicrobio.2014.03.027>.
  177. Lesho E, Yoon EJ, McGann P, Snesrud E, Kwak Y, Milillo M, Onmus-Leone F, Preston L, St Clair K, Nikolich M, Viscount H, Wortmann G, Zapor M, Grillot-Courvalin C, Courvalin P, Clifford R, Waterman PE. 2013. Emergence of colistin-resistance in extremely drug-resistant *Acinetobacter baumannii* containing a novel *pmrCAB* operon during colistin therapy of wound infections. *J Infect Dis* 208:1142–1151. <https://doi.org/10.1093/infdis/jit293>.
  178. Park YK, Choi JY, Shin D, Ko KS. 2011. Correlation between overexpression and amino acid substitution of the PmrAB locus and colistin resistance in *Acinetobacter baumannii*. *Int J Antimicrob Agents* 37: 525–530. <https://doi.org/10.1016/j.ijantimicag.2011.02.008>.
  179. Pournaras S, Poulou A, Dafopoulou K, Chabane YN, Kristo I, Makris D, Hardouin J, Cosette P, Tsakris A, Dé E. 2014. Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 58:828–832. <https://doi.org/10.1128/AAC.01439-13>.
  180. Rolain JM, Diene SM, Kempf M, Gimenez G, Robert C, Raoult D. 2013. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant *Acinetobacter baumannii* isolate from Marseille, France. *Antimicrob Agents Chemother* 57:592–596. <https://doi.org/10.1128/AAC.01314-12>.
  181. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. 2011. Insertion sequence IS*Aba11* is involved in colistin resistance and loss of lipopolysaccharide in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 55:3022–3024. <https://doi.org/10.1128/AAC.01732-10>.
  182. Ah YM, Kim AJ, Lee JY. 2014. Colistin resistance in *Klebsiella pneumoniae*. *Int J Antimicrob Agents* 44:8–15. <https://doi.org/10.1016/j.ijantimicag.2014.02.016>.
  183. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). *J Antimicrob Chemother* 66:2070–2074. <https://doi.org/10.1093/jac/dkr239>.
  184. Walky A, DeCorby M, Nichol K, Karlowsky JA, Hoban DJ, Zhanel GG. 2009. In vitro activity of colistin (polymyxin E) against 3,480 isolates of Gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007–2008. *Antimicrob Agents Chemother* 53: 4924–4926. <https://doi.org/10.1128/AAC.00786-09>.
  185. Sutherland CA, Nicolau DP. 2015. Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* from U.S. hospitals. *Clin Ther* 37:1564–1571. <https://doi.org/10.1016/j.clinthera.2015.05.501>.
  186. Tijet N, Sheth PM, Lastovetska O, Chung C, Patel SN, Melano RG. 2014. Molecular characterization of *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Enterobacteriaceae* in Ontario, Canada, 2008–2011. *PLoS One* 9:e116421. <https://doi.org/10.1371/journal.pone.0116421>.
  187. Bratu S, Tolaney P, Karumudi U, Quale J, Moity M, Nichani S, Landman D. 2005. Carbapenemase-producing *Klebsiella pneumoniae* in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. *J Antimicrob Chemother* 56:128–132. <https://doi.org/10.1093/jac/dki175>.
  188. Bogdanovich T, Adams-Haduch JM, Tian GB, Nguyen MH, Kwak EJ, Muto CA, Doi Y. 2011. Colistin-resistant, *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Klebsiella pneumoniae* belonging to the international epidemic clone ST258. *Clin Infect Dis* 53:373–376. <https://doi.org/10.1093/cid/cir401>.
  189. Marchaim D, Chopra T, Pogue JM, Perez F, Hujer AM, Rudin S, Endimiani A, Navon-Venezia S, Hothi J, Slim J, Blunden C, Shango M, Lephart PR, Salimnia H, Reid D, Moshos J, Hafeez W, Bheemreddy S, Chen TY, Dhar S, Bonomo RA, Kaye KS. 2011. Outbreak of colistin-resistant, carbapenem-resistant *Klebsiella pneumoniae* in metropolitan Detroit, Michigan. *Antimicrob Agents Chemother* 55:593–599. <https://doi.org/10.1128/AAC.01020-10>.
  190. Garza-Ramos U, Barrios H, Reyna-Flores F, Sanchez-Perez A, Tamayo-Legorreta E, Ibarra-Pacheco A, Salazar-Salinas J, Nunez-Ceballos R, Silva-Sanchez J. 2014. Characteristics of KPC-2-producing *Klebsiella pneumoniae* (ST258) clinical isolates from outbreaks in 2 Mexican medical centers. *Diagn Microbiol Infect Dis* 79:483–485. <https://doi.org/10.1016/j.diagmicrobio.2014.05.010>.
  191. Arduino SM, Quiroga MP, Ramirez MS, Merckier AK, Errecalde L, Di Martino A, Smayevsky J, Kaufman S, Centron D. 2012. Transposons and integrons in colistin-resistant clones of *Klebsiella pneumoniae* and *Acinetobacter baumannii* with epidemic or sporadic behaviour. *J Med Microbiol* 61:1417–1420. <https://doi.org/10.1099/jmm.0.038968-0>.
  192. Weterings V, Zhou K, Rossen JW, van Stenis D, Thewessen E, Kluytmans J, Veenemans J. 2015. An outbreak of colistin-resistant *Klebsiella pneumoniae* carbapenemase-producing *Klebsiella pneumoniae* in the Netherlands (July to December 2013), with inter-institutional spread. *Eur J Clin Microbiol Infect Dis* 34:1647–1655. <https://doi.org/10.1007/s10096-015-2401-2>.
  193. Toth A, Damjanova I, Puskas E, Janvari L, Farkas M, Dobak A, Borocz K, Paszti J. 2010. Emergence of a colistin-resistant KPC-2-producing *Klebsiella pneumoniae* ST258 clone in Hungary. *Eur J Clin Microbiol Infect Dis* 29:765–769. <https://doi.org/10.1007/s10096-010-0921-3>.
  194. Kontopoulou K, Protonotariou E, Vasilakos K, Kriti M, Koteli A, Antoniadou E, Sofianou D. 2010. Hospital outbreak caused by *Klebsiella pneu-*

- moniae* producing KPC-2 beta-lactamase resistant to colistin. *J Hosp Infect* 76:70–73. <https://doi.org/10.1016/j.jhin.2010.03.021>.
195. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H. 2007. Colistin-resistant isolates of *Klebsiella pneumoniae* emerging in intensive care unit patients: first report of a multiclonal cluster. *J Antimicrob Chemother* 59:786–790. <https://doi.org/10.1093/jac/dkl562>.
  196. Mezzatesta ML, Gona F, Caio C, Petrolito V, Sciortino D, Sciacca A, Santangelo C, Stefani S. 2011. Outbreak of KPC-3-producing, and colistin-resistant, *Klebsiella pneumoniae* infections in two Sicilian hospitals. *Clin Microbiol Infect* 17:1444–1447. <https://doi.org/10.1111/j.1469-0691.2011.03572.x>.
  197. Mammina C, Bonura C, Di Bernardo F, Aleo A, Fasciana T, Sodano C, Saporito MA, Verde MS, Tetamo R, Palma DM. 2012. Ongoing spread of colistin-resistant *Klebsiella pneumoniae* in different wards of an acute general hospital, Italy, June to December 2011. *Euro Surveill* 17:20248.
  198. Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, Henrici De Angelis L, Fornaini R, Grazzini M, Niccolini F, Pecile P, Rossolini GM. 2015. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing *Klebsiella pneumoniae* traced to clonal expansion of a *mgrB* deletion mutant. *J Clin Microbiol* 53:3341–3344. <https://doi.org/10.1128/JCM.01017-15>.
  199. Parisi SG, Bartolini A, Santacatterina E, Castellani E, Ghirardo R, Berto A, Franchin E, Menegotto N, De Canale E, Tommasini T, Rinaldi R, Basso M, Stefani S, Palu G. 2015. Prevalence of *Klebsiella pneumoniae* strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 to December 2014. *BMC Infect Dis* 15:244. <https://doi.org/10.1186/s12879-015-0996-7>.
  200. Mezzatesta ML, Caio C, Gona F, Cormaci R, Salerno I, Zingali T, Denaro C, Gennaro M, Quattrone C, Stefani S. 2014. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs. *Int J Antimicrob Agents* 44:112–116. <https://doi.org/10.1016/j.ijantimicag.2014.04.014>.
  201. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S, Grundmann H, Pantosti A, Rossolini GM. 2014. Colistin resistance superimposed to endemic carbapenem-resistant *Klebsiella pneumoniae*: a rapidly evolving problem in Italy, November 2013 to April 2014. *Euro Surveill* 19:20939. <https://doi.org/10.2807/1560-7917.ES2014.19.42.20939>.
  202. Meletis G, Oustas E, Botziro C, Kakasi E, Koteli A. 2015. Containment of carbapenem resistance rates of *Klebsiella pneumoniae* and *Acinetobacter baumannii* in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance. *New Microbiol* 38:417–421.
  203. Zagorianou A, Sianou E, Iosifidis E, Dimou V, Protonotariou E, Miyakis S, Roulides E, Sofianou D. 2012. Microbiological and molecular characteristics of carbapenemase-producing *Klebsiella pneumoniae* endemic in a tertiary Greek hospital during 2004–2010. *Euro Surveill* 17:20088.
  204. Pena I, Picazo JJ, Rodriguez-Avial C, Rodriguez-Avial I. 2014. Carbapenemase-producing *Enterobacteriaceae* in a tertiary hospital in Madrid, Spain: high percentage of colistin resistance among VIM-1-producing *Klebsiella pneumoniae* ST11 isolates. *Int J Antimicrob Agents* 43:460–464. <https://doi.org/10.1016/j.ijantimicag.2014.01.021>.
  205. Jayol A, Poirer L, Dortet L, Nordmann P. 2016. National survey of colistin resistance among carbapenemase-producing *Enterobacteriaceae* and outbreak caused by colistin-resistant OXA-48-producing *Klebsiella pneumoniae*, France, 2014. *Euro Surveill* 21:30339. <https://doi.org/10.2807/1560-7917.ES.2016.21.37.30339>.
  206. Suh JY, Son JS, Chung DR, Peck KR, Ko KS, Song JH. 2010. Nonclonal emergence of colistin-resistant *Klebsiella pneumoniae* isolates from blood samples in South Korea. *Antimicrob Agents Chemother* 54:560–562. <https://doi.org/10.1128/AAC.00762-09>.
  207. Tan TY, Ng SY. 2006. The in-vitro activity of colistin in Gram-negative bacteria. *Singapore Med J* 47:621–624.
  208. Chen S, Hu F, Zhang X, Xu X, Liu Y, Zhu D, Wang H. 2011. Independent emergence of colistin-resistant *Enterobacteriaceae* clinical isolates without colistin treatment. *J Clin Microbiol* 49:4022–4023. <https://doi.org/10.1128/JCM.01233-11>.
  209. Chiu SK, Wu TL, Chuang YC, Lin JC, Fung CP, Lu PL, Wang JT, Wang LS, Siu LK, Yeh KM. 2013. National surveillance study on carbapenem non-susceptible *Klebsiella pneumoniae* in Taiwan: the emergence and rapid dissemination of KPC-2 carbapenemase. *PLoS One* 8:e69428. <https://doi.org/10.1371/journal.pone.0069428>.
  210. Matthaïou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaïannou V, Ntani G, Samonis G, Falagas ME. 2008. Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: a matched case-control study. *Crit Care Med* 36:807–811. <https://doi.org/10.1097/CCM.0B013E3181652FAE>.
  211. Kontopidou F, Plachouras D, Papadomichelakis E, Koukous G, Galani I, Poulakou G, Dimopoulos G, Antoniadou A, Armaganidis A, Giamarellou H. 2011. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. *Clin Microbiol Infect* 17:E9–E11. <https://doi.org/10.1111/j.1469-0691.2011.03649.x>.
  212. Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandembroucke-Grauls CM. 2013. Emergence of colistin resistance in *Enterobacteriaceae* after the introduction of selective digestive tract decontamination in an intensive care unit. *Antimicrob Agents Chemother* 57:3224–3229. <https://doi.org/10.1128/AAC.02634-12>.
  213. Strenger V, Gschliesser T, Grisold A, Zarfel G, Feierl G, Masoud L, Hoenigl M, Resch B, Muller W, Urlesberger B. 2011. Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum beta-lactamase-producing enterobacteria in hospitalised newborns. *Int J Antimicrob Agents* 37:67–69. <https://doi.org/10.1016/j.ijantimicag.2010.09.010>.
  214. Durante-Mangoni E, Del Franco M, Andini R, Bernardo M, Giannouli M, Zarrilli R. 2015. Emergence of colistin resistance without loss of fitness and virulence after prolonged colistin administration in a patient with extensively drug-resistant *Acinetobacter baumannii*. *Diagn Microbiol Infect Dis* 82:222–226. <https://doi.org/10.1016/j.diagmicrobio.2015.03.013>.
  215. Silvestri L, Taylor N, van Saene HK, Bakker J. 2014. Colistin, SDD and resistance: nihil novi sub sole. *Intensive Care Med* 40:1065. <https://doi.org/10.1007/s00134-014-3321-9>.
  216. Zhao F, Zong Z. 2016. *Kluyvera ascorbata* strain from hospital sewage carrying the *mcr-1* colistin resistance gene. *Antimicrob Agents Chemother* 60:7498–7501.
  217. Skov RL, Monnet DL. 2016. Plasmid-mediated colistin resistance (*mcr-1* gene): three months later, the story unfolds. *Euro Surveill* 21:30155. <https://doi.org/10.2807/1560-7917.ES.2016.21.9.30155>.
  218. Hu Y, Liu F, Lin Y, Gao GF, Zhu B. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:146–147. [https://doi.org/10.1016/S1473-3099\(15\)00533-2](https://doi.org/10.1016/S1473-3099(15)00533-2).
  219. Ruppe E, Chatelier EL, Pons N, Andreumont A, Ehrlich SD. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:290–291. [https://doi.org/10.1016/S1473-3099\(16\)00066-9](https://doi.org/10.1016/S1473-3099(16)00066-9).
  220. Zhi C, Lv L, Yu LF, Doi Y, Liu JH. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:292–293. [https://doi.org/10.1016/S1473-3099\(16\)00063-3](https://doi.org/10.1016/S1473-3099(16)00063-3).
  221. Zhang R, Huang Y, Chan EW, Zhou H, Chen S. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:291–292. [https://doi.org/10.1016/S1473-3099\(16\)00062-1](https://doi.org/10.1016/S1473-3099(16)00062-1).
  222. Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:147. [https://doi.org/10.1016/S1473-3099\(15\)00540-X](https://doi.org/10.1016/S1473-3099(15)00540-X).
  223. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT, Pham NT, Goossens H. 2016. Colistin-resistant *Escherichia coli* harbouring *mcr-1* isolated from food animals in Hanoi, Vietnam. *Lancet Infect Dis* 16:286–287. [https://doi.org/10.1016/S1473-3099\(16\)00014-1](https://doi.org/10.1016/S1473-3099(16)00014-1).
  224. Stoesser N, Mathers AJ, Moore CE, Day NP, Crook DW. 2016. Colistin resistance gene *mcr-1* and pHNSHP45 plasmid in human isolates of *Escherichia coli* and *Klebsiella pneumoniae*. *Lancet Infect Dis* 16:285–286. [https://doi.org/10.1016/S1473-3099\(16\)00010-4](https://doi.org/10.1016/S1473-3099(16)00010-4).
  225. Petrillo M, Angers-Loustau A, Kreysa J. 2016. Possible genetic events producing colistin resistance gene *mcr-1*. *Lancet Infect Dis* 16:280. [https://doi.org/10.1016/S1473-3099\(16\)00005-0](https://doi.org/10.1016/S1473-3099(16)00005-0).
  226. Suzuki S, Ohnishi M, Kawanishi M, Akiba M, Kuroda M. 2016. Investigation of a plasmid genome database for colistin-resistance gene *mcr-1*. *Lancet Infect Dis* 16:284–285. [https://doi.org/10.1016/S1473-3099\(16\)00008-6](https://doi.org/10.1016/S1473-3099(16)00008-6).
  227. Haenni M, Poirer L, Kieffer N, Chatre P, Saras E, Metayer V, Dumoulin R, Nordmann P, Madec JY. 2016. Co-occurrence of extended spectrum  $\beta$ -lactamase and MCR-1 encoding genes on plasmids. *Lancet Infect Dis* 16:281–282. [https://doi.org/10.1016/S1473-3099\(16\)00007-4](https://doi.org/10.1016/S1473-3099(16)00007-4).
  228. Perrin-Guyomard A, Bruneau M, Houe P, Deleume K, Legrandois P, Poirier C, Soumet C, Sanders P. 2016. Prevalence of *mcr-1* in commensal *Escherichia coli* from French livestock, 2007 to 2014. *Euro Surveill* 21:30135. <https://doi.org/10.2807/1560-7917.ES.2016.21.6.30135>.
  229. Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F, Rossolini GM.

2016. First detection of the *mcr-1* colistin resistance gene in *Escherichia coli*, Italy. *Antimicrob Agents Chemother* 60:3257–3258. <https://doi.org/10.1128/AAC.00246-16>.
230. Giufrè M, Monaco M, Accogli M, Pantosti A, Cerquetti M, PAMURSA Study Group. 2016. Emergence of the colistin resistance *mcr-1* determinant in commensal *Escherichia coli* from residents of long-term-care facilities in Italy. *J Antimicrob Chemother* 71:2329–2331. <https://doi.org/10.1093/jac/dkw195>.
231. Doumith M, Godbole G, Ashton P, Larkin L, Dallman T, Day M, Day M, Muller-Pebody B, Ellington MJ, de Pinna E, Johnson AP, Hopkins KL, Woodford N. 2016. Detection of the plasmid-mediated *mcr-1* gene conferring colistin resistance in human and food isolates of *Salmonella enterica* and *Escherichia coli* in England and Wales. *J Antimicrob Chemother* 71:2300–2305. <https://doi.org/10.1093/jac/dkw093>.
232. Kluytmans-van den Bergh MF, Huizinga P, Bonten MJ, Bos M, De Bruyne K, Friedrich AW, Rossen JW, Savelkoul PH, Kluytmans JA. 2016. Presence of *mcr-1*-positive *Enterobacteriaceae* in retail chicken meat but not in humans in the Netherlands since 2009. *Euro Surveill* 21:30149. <https://doi.org/10.2807/1560-7917.ES.2016.21.9.30149>.
233. Bonten MJ. 2016. Antimicrobial resistance: is it really all going wrong now? *Ned Tijdschr Geneesk* 160:D81.
234. Arcilla MS, van Hattem JM, Matamoros S, Melles DC, Penders J, de Jong MD, Schultz C. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:147–149. [https://doi.org/10.1016/S1473-3099\(15\)00541-1](https://doi.org/10.1016/S1473-3099(15)00541-1).
235. Veldman K, van Essen-Zandbergen A, Rapallini M, Wit B, Heymans R, van Pelt W, Mevius D. 2016. Location of colistin resistance gene *mcr-1* in *Enterobacteriaceae* from livestock and meat. *J Antimicrob Chemother* 71:2340–2342. <https://doi.org/10.1093/jac/dkw181>.
236. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agero Y, Zankari E, Leekitcharoenphon P, Stegger M, Kaas RS, Cavaco LM, Hansen DS, Aarestrup FM, Skov RL. 2015. Detection of *mcr-1* encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat, Denmark 2015. *Euro Surveill* 20:30085. <https://doi.org/10.2807/1560-7917.ES.2015.20.49.30085>.
237. McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R, Hinkle M, Whitman T, Lesho E, Schaecher KE. 2016. *Escherichia coli* harboring *mcr-1* and *bla<sub>CTX-M</sub>* on a novel IncF plasmid: first report of *mcr-1* in the United States. *Antimicrob Agents Chemother* 60:4420–4421. <https://doi.org/10.1128/AAC.01103-16>.
238. Grami R, Mansour W, Mehri W, Bouallegue O, Boujaafar N, Madec JY, Haenni M. 2016. Impact of food animal trade on the spread of *mcr-1*-mediated colistin resistance, Tunisia, July 2015. *Euro Surveill* 21:30144. <https://doi.org/10.2807/1560-7917.ES.2016.21.8.30144>.
239. Elnahryy SS, Khalifa HO, Soliman AM, Ahmed AM, Moustafa AH, Shimamoto T. 2016. Emergence of plasmid-mediated colistin resistance gene, *mcr-1*, in a clinical *Escherichia coli* isolate from Egypt. *Antimicrob Agents Chemother* 60:3249–3250. <https://doi.org/10.1128/AAC.00269-16>.
240. Perreten V, Strauss C, Collaud A, Gerber D. 2016. Colistin resistance gene *mcr-1* in avian pathogenic *Escherichia coli* in South Africa. *Antimicrob Agents Chemother* 60:4414–4415. <https://doi.org/10.1128/AAC.00548-16>.
241. Fernandes MR, Moura Q, Sartori L, Silva KC, Cunha MP, Esposito F, Lopes R, Otutumi LK, Gonçalves DD, Dropa M, Matté MH, Monte DF, Landgraf M, Francisco GR, Bueno MF, de Oliveira Garcia D, Knöbl T, Moreno AM, Lincopan N. 2016. Silent dissemination of colistin-resistant *Escherichia coli* in South America could contribute to the global spread of the *mcr-1* gene. *Euro Surveill* 21:30214. <https://doi.org/10.2807/1560-7917.ES.2016.21.17.30214>.
242. Zeng KJ, Doi Y, Patil S, Huang X, Tian GB. 2016. Emergence of plasmid-mediated *mcr-1* gene in colistin-resistant *Enterobacter aerogenes* and *Enterobacter cloacae*. *Antimicrob Agents Chemother* 60:3862–3863. <https://doi.org/10.1128/AAC.00345-16>.
243. Tse H, Yuen KY. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:145–146. [https://doi.org/10.1016/S1473-3099\(15\)00532-0](https://doi.org/10.1016/S1473-3099(15)00532-0).
244. Webb HE, Granier SA, Marault M, Millemann Y, den Bakker HC, Nightingale KK, Bugarel M, Ison SA, Scott HM, Loneragan GH. 2016. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 16:144–145. [https://doi.org/10.1016/S1473-3099\(15\)00538-1](https://doi.org/10.1016/S1473-3099(15)00538-1).
245. Iraz M, Ozad Duzgun A, Sandalli C, Doymaz MZ, Akkoyunlu Y, Saral A, Peleg AY, Ozgumus OB, Beris FS, Karaoglu H, Copur Cicek A. 2015. Distribution of beta-lactamase genes among carbapenem-resistant *Klebsiella pneumoniae* strains isolated from patients in Turkey. *Ann Lab Med* 35:595–601. <https://doi.org/10.3343/alm.2015.35.6.595>.
246. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. 2009. Carbapenem resistance among *Klebsiella pneumoniae* isolates: risk factors, molecular characteristics, and susceptibility patterns. *Infect Control Hosp Epidemiol* 30:666–671. <https://doi.org/10.1086/598244>.
247. Lee JY, Chung ES, Na IY, Kim H, Shin D, Ko KS. 2014. Development of colistin resistance in *pmrA*-, *phoP*-, *parR*- and *cprR*-inactivated mutants of *Pseudomonas aeruginosa*. *J Antimicrob Chemother* 69:2966–2971. <https://doi.org/10.1093/jac/dku238>.

**Laurent Poirel**, Ph.D., is an Associate Professor in the Medical and Molecular Microbiology Unit, Department of Medicine, University of Fribourg, Switzerland. His research interests focus on antibiotic resistance in Gram-negative bacteria, with a special focus on the identification of molecular mechanisms responsible for acquisition of carbapenem and polymyxin resistance and the genetics of acquisition of resistance genes.



**Aurélien Jayol**, Pharm.D., is a Microbiologist currently preparing a Ph.D. thesis at the University of Fribourg, Switzerland. Her research interests focus on antibiotic resistance, especially the molecular mechanisms responsible for acquisition of colistin resistance in *Enterobacteriaceae* and the use of diagnostic tests for detection of colistin resistance.



**Patrice Nordmann**, M.D., Ph.D., is Chair Professor and Head of the Medical and Molecular Microbiology Unit of the French INSERM European Unit (University of Fribourg) of the National Reference Center for Emerging Antibiotic Resistance (Switzerland), Department of Medicine, University of Fribourg, Switzerland. His research interests focus on antibiotic resistance in Gram-negative bacteria, encompassing identification of molecular mechanisms, performance of epidemiological surveys, development of rapid diagnostic tests for antibiotic resistance, and development of novel antibiotic molecules.

